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 Abstract  
 
China is an emerging force in undertaking randomised clinical trials.  The 
quality of trials from China may affect not only its own substantial population 
but also potentially contribute to health policy throughout the world.  However, 
little is known about the quality of clinical trials conducted there. In this thesis, 
I will evaluate the quality of published Chinese randomised controlled trials 
(RCTs) by comparing them with Indian RCTs as well as a set of ‘gold 
standard’ trials reported in leading European and North American journals.  I 
will also describe and contrast the quality and biases within Chinese RCTs.  I 
then explore the reasons for these differences from the point of view of the 
major RCT stakeholders: Chinese clinicians and patients. The potential 
influences from Chinese traditional culture is also evaluated. 
 
I conducted both quantitative and qualitative research in this thesis.  The first 
systematic review was about randomised controlled trials (RCTs) conducted 
in China and published in 2004.  This was undertaken to describe their 
characteristics, assess the quality of their reporting, and where possible, the 
quality of their conduct. The second systematic review was to undertake a 
comparative empirical analysis of RCT reports published in selected Chinese, 
Indian and European or North American medical journals. Quality was 
assessed against a subset of criteria from the CONSORT statement. I 
compared the rate of reporting of positive outcomes in clinical trials to 
describe potential bias.  I also conducted qualitative research in 3 hospitals of 
Guangzhou, interviewing clinicians and patients to explore their understanding, 
 attitude and personal experiences toward conducting and participating in 
RCTs. 
 
Three hundred and seven Chinese papers, 117 Indian papers and 304 
Western papers were included. In the Chinese papers, 199 (64.8%) failed to 
report methods of randomization and 254 (82.4%) did not report blinding of 
either participants or investigators. Reporting of baseline characteristics, 
primary outcome and length of follow-up was inadequate in a substantial 
proportion of studies. Fewer than 11% of RCTs described ethical approval 
and only 18% adequately discussed informed consent. However, dropout 
rates were favourable, with nearly 44% of trials reporting a zero dropout rate.  
Reports of Indian trials were slightly better than Chinese papers on trial 
reporting quality indicators and much better than Chinese papers on reporting 
patients’ ethical issues. However Western trial reports scored considerably 
higher on all quality criteria. Non-linear mixed models with a logit link and 
binomial/ normal error inferred that Chinese papers were substantially more 
likely to report statistically significant results (OR=2.96, 95% CI 2.23 to 3.94; 
P<0.0001). Indian trials reported a similar rate of positive results to the gold 
standard Western papers (OR=0.92, 95% CI 0.69 to 1.24; P=0.59).   
The RCT as a research method was developed in Western countries and 
exported to China. This created potential conflict within the traditional Chinese 
medical system, including the doctor-patient relationship and issues of ethics. 
Chinese clinicians have the dilemma of being either a clinical doctor or of 
being a medical researcher. Chinese culture and the current Chinese medical 
system block doctors’ understanding of and participation in RCT research. 
 Chinese patients place extreme trust in their clinicians, therefore Chinese 
clinicians find it easy to recruit patients to RCTs and this is also reflected in 
the good compliance rate. However, the uncertainty from involvement in? 
RCTs affects the trust between clinicians and patients. 
The reporting of trials in major Chinese and Indian journals is inadequate, and 
may reflect underlying inadequacies in the design and conduct of these trials.  
Chinese trials appear biased and may selectively report positive outcomes 
while ignoring neutral or negative outcomes. In order to improve the quality of 
RCT reporting and conduct, the Chinese medical system needs to make 
changes at a systemic level. Research work should be considered as an 
important part of being a modern Chinese clinician. Journal editors in China 
and India should adopt the CONSORT reporting guidelines, should ensure 
that a primary outcome is prespecified and reported, and should ensure that 
analysis is conducted according to the intention to treat principle.  Ethical 
questions in the conduct of trials in China must be addressed.   
 
Four years after my first study of the quality evaluation of Chinese RCTs, I 
also updated my review of the quality of Chinese trials and compared it with 
my previous systematic review result, hoping to detect an improvement in the 
quality of Chinese RCTs  
 
Two hundred and forty-two papers were included. Compared to my previous 
research, Chinese published RCTs had a significant improvement on their 
description of informed consent, ethical committee approval and the reporting 
of a primary outcome. 11 (4.6%) RCTs reported adequate concealment of 
 patient allocation, and, 100% of the papers used P value to describe the 
results from statistical tests. Compared to 2004, the positive result rate OR= 
1.01, 95% CI 0.81 to 1.27, P=0.93. 
 
Ethical committee approval and reporting of participants’ informed consent 
have been improved significantly. However, reporting of RCTs in China needs 
substantial improvement to meet the target of the CONSORT statement. 
 
Chinese medical journal editors need to undertake more training on the 
reporting of RCTs; all medical societies should take more concern about 
doctors’ research work; the Chinese public media should help the general 
population to understand more about RCT principles. 
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Chapter 1.  INTRODUCTION 
 
Outline 
In this chapter, I will introduce the basic knowledge and important theory 
relating to the conduct and reporting of Randomised Controlled Trials.   
  
Randomized controlled trials (RCT) are considered the ‘gold standard’ for 
assessing the effectiveness of pharmacological and other interventions in the 
field of medicine1-4, which provide the best evidence on the effects of health 
care interventions.  They are widely accepted as the best research design 
because they distribute both known and unknown prognostic factors between 
treatment groups by the play of chance thereby minimising the possibility that 
any treatment effect is due to bias or confounding (that is, other factors which 
are systematically different between the treatment groups), and providing the 
basis for valid statistical comparison5-8.  Reports of RCTs provide evidence for 
health care providers and policy makers to make decisions on whether to use 
new health technologies in their patients.  However, RCTs vary in their 
methodological rigour, and it is well known that poor quality studies tend to 
produce systematically different results from larger, better quality studies; 
often erroneously showing larger treatment effects.9;10  Many medical journals 
now expect authors to adhere to internationally agreed standards of reporting 
thus allowing the reader to assess the conduct of each trial11. In order to 
maximise the benefits from increased knowledge, a high-quality publication 
should always report the characteristics and results of a RCT.  Previous work 
has indicated that the methodological quality of an RCT is reflected in the 
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quality of such reports12;12;13 Through the RCT publications I can thus evaluate 
the trial’s conduct and quality in developing research contexts.  
 
1.1 Clinical trial 
 
Evaluation of the effectiveness of treatments for diseases has historically 
been fraught with problems and was often not conducted in a systematic way. 
It is now generally accepted that well conducted clinical trials are the most 
reliable means for evaluating the efficacy and safety of new treatments. 
 
 
1.2 Clinical trials and statistics 
 
Statistics play an important role in medical research, including generalizing 
observations and combining knowledge. Randomised controlled trials are 
considered to be the best combination of clinical observation and statistics14 . 
 
A clinical trial is an experiment testing medical treatment on human subjects.  
Sir Austin Bradford Hill described clinical trials elegantly l15: 
 
In the assessment of a treatment, medicine always has proceeded and always 
must proceed, by way of experiment. The experiment may merely consist in 
giving the treatment to particular patient or series of patients and of observing 
and recording what follows- with all the difficulty of interpretation. Of 
distinguishing the propter hoc from the post hoc. Nevertheless, even in these 
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circumstances and in face of unknown a question has been asked of nature, 
and it has been asked by means of trial in human being. There can be no 
possible escape from that. This is human experimentation of one kind at least. 
Somebody must be the first to exhibit a new treatment in man. Some patient, 
whether for good or ill, must be first to be exposed to it. 
 
1.3 Bias and Bias control 
 
‘Bias’ is a deviation that is not a consequence of chance alone16. The direct 
consequences of bias may be impossible to see. However, some biases, such 
as patient selection effects, appear to be strong compared with the modest 
size of many treatment effects. Cochrane handbook had summarised different 
types of biases in clinical trials in table, which I used partly in table 1.1 , 
 
Table 1.1. Bias categories and effects16 (part of Cochrane handbook for system 
reviewers of interventions) 
 
Type of bias Description 
Selection bias. Systematic differences between baseline characteristics of the 
groups that are compared. 
Performance bias. Systematic differences between groups in the care that is provided, 
or in exposure to factors other than the interventions of interest. 
Attrition bias. Systematic differences between groups in withdrawals from a 
study. 
Detection bias. Systematic differences between groups in how outcomes are 
determined. 
Reporting bias. Systematic differences between reported and unreported findings. 
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There are many types of bias in medical studies. In randomized trials, 
selection bias may not be as serious a problem, because it affects each group 
equally and therefore does not influence the estimated treatment difference. 
Selection bias is not the only one which made effect to clinical studies, 
Treatment administration, outcome assessment and counting endpoints can 
be biased either. 
 
Statistical biases are those that arise from using certain methods, test and 
analysis procedures and selection from alternative procedures. A preferential 
selection of positive study result rather than neutral or negative results leads 
to reporting bias. Another strong bias in data analysis is from inappropriate 
exclusion of eligible study subjects, that is  called attrition bias. Usually, there 
are some excellent clinical reasons for making these exclusions, therefore this 
kind of bias is difficult to eliminate.  
 
Detection bias is another potential difficulty. Patients and clinicians’ self-
assessments and report will not be objective if they have personal expectation 
on treatment. Therefore trial designs that use subjective assessment are 
necessary and important. 
  
There were studies indicating that in trials with subjective outcomes effect 
estimates were exaggerated when there was inadequate or unclear allocation 
concealment or lack of blinding17. There was little evidence of bias in trials 
with objective outcomes. The average bias associated with defects in the 
conduct of randomised trials varies with the type of outcome. 
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1.3.1 Randomization  
Randomization is the principal method to reduce selection bias. It is effective 
because it guarantees the differences between the treatment groups are only 
attributable to chance, the effect from chance can be accounted through 
statistics. Therefore, the remaining differences can be attributed to the 
treatment. The benefit of randomization is that it prevents confounding, even if 
the investigator is unaware that the effects exist or has not measured them. 
 
Chance was explained in many ways which relative to God or chaos, which is 
an unpredictable issue, As Barrow said in his brief but interesting discussion18 
 
‘Dabbling with random devices was serious theological business. Not 
something to be trifled with [or] merely studied for the fun of it.’ 
 
In WesternWestern science, randomization was used in medical studies by 
Bradford Hill and Richard Doll in Great Britain in the 1940s14, Randomisation 
is widely used for preventing bias in allocating treatments in comparative 
clinical trials. Randomization does not secure complete objectivity in a trial 
and must be combined with other design strategies to reduce bias14. 
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1.3.2 Blinding 
Blinding is an important mean to reduce assessment bias. ‘Single blind’ 
means that the participants in the study are unaware of which treatment they 
receive. ‘Double blind’ means both participators and clinicians are unaware of 
treatment. In order to make blinding work properly in practice, placebo is 
usually helped to make sure the treatment which look, taste and feel same to 
participants. A masked placebo control is different from a no-treatment control. 
In the latter case, the difference of treatment will include ‘placebo effect’ which 
is from participants’ personal expectation of the treatment. For example, in 
studies comparing analgesics16, patients might overstate the benefit if they 
know they are receiving a new drug. Thus, blinding can improve objectivity 
among participants and investigators. 
 
Double blinding further increases the usefulness of subjective endpoints, 
because investigators can also be influenced by their expectations16.  This is 
especially true if the investigator has been exposed to seemingly favourable 
pre-clinical data, believes strongly in the biological basis on which the therapy 
was developed, or has professional or financial interest in the success of the 
study. Effective treatment masking is essential in such cases.  
 
1.3.3 Objective assessments 
In clinical trials, the methods of evaluating study endpoints should be objective 
in order to minimize assessment bias and increase the reproducibility of 
findings.  
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1.3.4 Active follow-up and endpoint ascertainment 
Attention should be given to methods of assessing endpoint, even if these 
endpoints can be objectively defined, such as disease recurrence and death. 
If a trial relies only on passive reporting of such events, the chance for bias is 
increased.  
  
 
1.3.5 Concealment 
Proper allocation concealment helps to ensure the random allocation in trials.  
Without adequate allocation concealment, the effectiveness of random, 
unpredictable assignment sequences can be compromised9;19;20. In practice, 
in taking care of individual patients, clinical investigators often find it difficult to 
maintain impartiality. In order to dictate the allocation of their next patient, 
investigators hold up sealed envelopes to lights21. This introduces selection 
biases and confounding to the results of the study.  
 
Piantadosi suggested the following standard methods of ensuring allocation 
concealment include16: 
• Sequentially-Numbered, Opaque, Sealed Envelopes (SNOSE)  
• Sequentially-numbered containers  
• Pharmacy controlled  
• Central randomization, Central allocation （Which has become the 
most commonly used in large RCTs approach these days） 
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1.3.6 Intention-to-treat 
Intention-to-treat (ITT) was consider as a principle that patients should be 
analysis in randomised controlled trial. All randomised patients should be 
involved in analysis, ‘regardless of their adherence with entry criteria, 
regardless of the treatment they actually received, regardless of subsequent 
withdrawal from treatment’22.  
 
1.4 Ethical issues 
1.4.1 The Helsinki Declaration 
Helsinki declaration is widely adopted all over the world, which includes full 
issues of ethics for clinician engaged in clinical research23. It strengthen that 
individual patients’ interest is prior to any biomedical and clinical research. It 
outlines some principles; including those research involving human subjects 
must conform to generally accept scientific principles, having a written 
protocol, be conducted only by qualified individuals and include written 
informed consent from the participants. 
 
1.4.2 Clinician’s new role  
Statisticians have long played a significant role in clinical trials, in purely 
clinical tasks, there is relatively little need for statistical and reasoning14. 
Clinical researches require clinicians taking researcher’s roles including 
critical and quantitative views of research designs and data, which are 
different to clinician’s traditional role in clinic. Clinicians are required to 
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perform, report, and interpret clinical research studies requires statistical 
modes of reasoning.  
 
1.4.3 Ethic issue of clinical research 
Ethical considerations should be of continuing concern through the design 
and conduct of clinical trial. The general ethical requirements of clinical 
research world wide are outlined in the declaration of Helsinki issued by the 
World Medical Association. This brief document has been accepted 
internationally as the basis for ethical research23. 
 
  1.4.3.1 Individual versus collective ethics 
Individual ethics imply that each patient should receive that treatment which is 
best benefit to his health condition. This is the clear aim of good clinical 
practice in which the patient and his doctor decide together on what is the 
best course of action. Usually clinicians would determine therapy on the basis 
of his knowledge, experience and opinion with appropriate acknowledgement 
of patient’s wishes. 
 
Collective ethics is concerned with achieving medical progress as efficiently 
as possible so that all patients may subsequently benefit from superior 
therapy. One could argue that collective ethics is aimed at future patients 
while individual ethics is about that patient who requires treatment now. 
‘Exclusive adherence to collective ethics is an unacceptable stance to adopt’24. 
However, There is research demonstrating that patients in trials are better 
cared for than those in general clinical practice.25 
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 1.4.3.2 Informed consent 
The declaration of Helsinki states that in clinical research ‘the doctor should 
obtain the subject’s free-given informed consent, preferably in writing’.  
 
Informed consent is a vital concern in clinical trials23. There are numerous 
examples of studies where patients have been exposed to potentially or 
definitely harmful treatments without being fully appraised of the potential risks. 
Sick or dying patients and their families are vulnerable and it is questionable 
how much technical information about new treatments they can truly 
understand, especially when it is presented to them quickly or at a time of 
crisis. This problem arises when using treatments already know to be effective 
as well as when testing experiments ones. It is interesting that informed 
consent procedures, originally developed to protect research subjects from 
exploitation, are now viewed by many practitioners as devices to protect 
themselves from litigation23. 
 
1.5 The quality standard of RCT publications 
Study, design, conduct and writing up are closely related. We conduct studies 
not only to test hypotheses but also to share the results to broaden the 
community’s knowledge. A good report will give details on how the study was 
conducted so the reader may consider the applicability of the study’s 
population, intervention and results to his or her own patients. It follows that a 
study then needs to be conducted in a way that captures important reporting 
details----descriptors of the study population and appropriate documentation 
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of outcomes. Thus, it is appropriate to consider the details and article will 
report while the study is being designed.  
 
In Chan’s study,[ref] they found there were some differences between the 
study protocol and the final research publications on the report of outcomes. 
Outcomes with negative results were more often ‘ignored’ in final publications, 
which was considered a publication bias. However, there is limited research 
on detecting differences of RCT quality issues between reporting and what 
actually happened.  
 
 
1.5.1 The CONSORT statement 
In 1996, a group of scientist, editors and statisticians assembled to objectively 
evaluate what elements of an article were necessary for reader to assess the 
validity of a study’s background, conduct, results and conclusions11. The 
Consolidated Standards for Reporting Trials (CONSORT) statement was 
developed to guide the reporting of randomized controlled trials (RCTs). The 
original 50 items detailing essential reporting elements of the title, abstract, 
introduction, method, results and discussion were simplified to 22 in 2001 and 
have become the standard of reporting in most major medical journals for 
RCTs27. More than 25 % of the CONSORT statement focuses on methods of 
randomization, masking and follow-up of the large cohort in RCTs10.  
 
The publication of CONSORT statement in 1996 was an important step 
toward improving, reporting, standards. That year, Ophthalmology and several 
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other medical journals adopted the CONSORT standards and subsequently 
the revision in 200127. The first study of CONSORT standard compliance in 
the reporting ophthalmology RCT from 1991 to 1994 was published by 
Scherer and Crawley28. In 2001, Sanchez-Thorin and colleagues conducted a 
similar analysis and found that the quality of RCT reporting had improved 
since the adoption of the CONSORT standards, but still left ‘room for 
improvement’.29 Nowadays, standards of scientific reporting have evolved 
from very beginning of scientific reporting. Virtually all journals now publish 
instructions for authors and most medical journals adhere to certain standards 
of publication. The  CONSORT statement have been promoted by 
international groups such as the International Committee of Medical  Journal 
Editors (ICMJE) and Committee on Publication Ethics (COPE), which is the 
general RCT requirement of all leading medical journals30.  
 
1.5.2 ICH-E9 
ICH-E9 was the first comprehensive document of its kind to create a single 
global reference for a broad range of statistical principles in clinical trials31. It 
also helped establish a foundation for the practice of statistics in clinical trials 
for statisticians and non-statisticians worldwide. While statisticians have long 
played a significant role in clinical trials in some parts of the world, ICH-E9 
gave a credible voice to statisticians who need an authoritative reference on 
topics of great relevance for the scientific design, conduct, analysis and 
interpretation of clinical trials31. In that sense, it brought statistical 
considerations to a broad audience of scientists involved in clinical trials. 
Although ICH-E9 served us very well over the last decade, and its principles 
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are as valid today as ever, it may be time to supplement the document with 
current issues and thinking.  
 
ICH-E9 has achieved much of its overarching goal of harmonization of 
statistical practice in regulated clinical research for drug development, there 
are evidence show that protocol development, statistical  analysis planning 
and even the role of the statistician have changed in many positive regards32.   
ICH-E9 has also served as an excellent educational tool for statisticians 
embarking on a career in clinical trials. It is widely known and referenced by 
pharmaceutical statisticians.  
 
ICH –E9 put in one place a wide range of major topics for consideration and 
defined consensus opinions for the underlying statistical and scientific 
principles relevant to those topics. Besides definitive statements on well-worn 
topics such as bias, randomization and multiplicity, it brought greater focus 
and clarity to33: 
? Intention-to- treat (ITT) and defined a new concept termed the full analysis 
set, which allowed the proper use of ITT principles in a typical trial of new 
medicine. 
? Confirmatory versus exploratory trials, although the latter garnered limited 
discussion and was defined by exclusion. 
? Interim analysis and Interim Data Monitoring Committees. 
? Superiority and non-inferiority, although it fell short on the issue of the 
definition of effect ‘margin’. 
                                                                                                                              - 14 - 
? Pre-specified statistical analysis plans and the need to stipulate not only 
the analysis methodologies, but also the handing of protocol 
deviations/violation that impact analyses. 
 
 
 
 
 
1.6 Research background 
1.6.1 General introduction 
Chinese medical authors and chief medical editors appear all to be clinicians.  
The Chinese Medical Association is the main medical organization of Chinese 
medical doctors, which includes 82 branch associations on different disease 
areas and 430,000 members across mainland China34. The journal series of 
the Chinese Medical Association includes 71 journals, which comprise the 
core medical journals in Mainland China. The Chinese Medical Association is 
an academic and non-government organization and its members are all 
qualified medical professionals. The journal series includes the most 
influential medical journals, which should represent the highest quality of 
Chinese medical research. The leading Medical editors are all clinicians; they 
view and make comments on medical publications for the journal series of the 
Chinese Medical Association. Therefore, I concentrate on clinicians as my 
research group as the most important group who influence the conduct and 
reporting of Chinese randomized controlled trials. 
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I searched in both Chinese and English language but found no similar 
research had been done before on a Chinese population. Therefore, I 
conducted a series of qualitative research interviews with clinicians and 
patients, including personal interviews of senior doctors and patients and 
focus group meetings of junior doctors in order to explore their knowledge and 
attitude towards randomized controlled trials. The purpose of this was to 
explore the reasons for Chinese medical authors producing unsatisfactory 
RCT papers and to attempt to identify the barriers to conducting and reporting 
better RCTs, as well as exploring what could be done to improve the quality of 
RCTs.   
 
 
 
1.6.2  Health in China and Guangzhou 
 
China is one of the largest countries in the world. It expands to over 9.6 million 
square kilometers and houses a population of more than 1.3 billion people. It 
consists of 23 provinces, 5 autonomous regions, 4 municipalities and Hong 
Kong and Macao special Administrative regions. 
 
The rapid economic development after the reform and opening up policy, 
especially the economic transformation in recent years, has resulted in 
improved living conditions, nutrition and health care. The birth rate has 
decreased from 33.43‰ in 1970 to 12.40‰ in 200535.The death rate has 
decreased from 7.6‰ in 1970 to 6.51‰ in 2005. Infant mortality decreased 
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from 47.0‰ in 1970’s to 32.2‰ in 200036.  Life expectancy increased from 
66.4 to 69.6 in men and from 69.3 to 73.3 in women during 1981 to 200037. 
 
 
 
 
 
 
Figue 1.1 location of Guangzhou  
 
Guangdong is a big province in south China with a population of 
91,940,000.(2005 projection from China Ministry of Health). Guangzhou is the 
provincial capital of Guangdong province. (Figure 1.1) It is a city of more than 
10 million population. The birth rate and the death rate in Guangzhou are 
9.56‰ and 5.74‰ respectively in 2004, which are slightly lower than the 
national level. Guangzhou is the leading economic and cultural city in 
southern China.  
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1.6.3 General introduction of medical doctor 
 
A physician, medical practitioner or medical doctor is a person who practices 
medicine and is concerned with maintaining or restoring human health 
through the study, diagnosis and treatment of disease and injury38.  
 
Medical doctors are traditionally considered to be members of a learned 
profession because of the extensive training requirements and also because 
of the occupation's special ethical and legal duties. Physicians are often 
members, or fellows of local professional organizations.38  
 
In ancient history medical issues were strongly connected to magic. All human 
societies have medical beliefs that provide explanations for birth, death, and 
disease. Throughout history illness has been attributed to witchcraft, demons, 
adverse astral influence, or the will of the Gods39. These ideas still retain 
some power with faith healing and shrines still used in some places, although 
the rise of scientific medicine over the past millennium has altered or replaced 
many of the old beliefs. The practice of medicine has ancient associations 
with religion and magic; healers were treated as a god to save people from 
ailments, for example, in China, famous ancient doctors are all named as 
‘medical god’ or ‘magic doctor’. The traditional relationship between the doctor 
and patient is like the relationship between a magic saint and a normal person; 
patients consequently have extreme respect for doctors40. 
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In China, medical doctors belong to the upper-social class41, even in poor 
rural areas. Most hospitals are located in downtown areas due to people’s 
reliance on public transportation in China. More than 80% of Chinese medical 
resources are concentrated in urban areas, and the rest in rural areas. 
Medical doctors are considered scientific professionals and are 
representatives of modern science.  
 
 
 
1.6.4 Chinese hospital system 
 Chinese hospitals are classified as three general levels, with level 3 at the top 
and level 1 at the bottom41. Each level has sub-levels of A, B and C. Some 
elite hospitals are 3As. Physicians used to be hired as full-time and lifetime 
employees at a government controlled hospital. But both physicians and 
hospitals now have more freedom in choosing each other. 
 
For a government-controlled hospital42, the hospital is still operated and 
managed by a management team under the leadership of the president of the 
hospital, who is usually nominated and appointed by the healthcare 
department of a province, a city or a county. However, for a private hospital or 
a publicly traded hospital, the ownership is the same as that of a private 
company or a public company. Medical doctors usually have an employment 
contract with the hospital they work with, and a person can quit at will. The 
hospital can also terminate the individual’s employment if they are not 
satisfied with the employee’s performance or morality. 
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Not all Chinese hospitals could currently conduct clinical trials. The Chinese 
Food and Drug Administration had a strict regulation for all the hospitals on 
clinical trial activities. Only those hospitals considered to provide superior 
medical techniques and with clinicians with adequate clinical trial knowledge 
which pass the evaluation from CFDA will have the approval to conduct 
clinical trials. For different phases of clinical trial, the required standards vary. 
Through gaining appropriate qualification, the hospital could participated in 
medical research, especially those multi-centre, international randomised 
controlled trial are which may appear quite attractive.  Therefore, this 
qualification is consider as an honour to many hospitals. The requirements are 
more like to be achieved by those 3A hospitals, those big hospitals with a 
large number of clinicians. There are 449 hospitals in Guangzhou, 28 of them 
are 3A hospitals.  
 
 
1.6.5 RCT in Chinese medical education  
RCT Research is a new word to traditional Chinese clinicians43, but 
methodological courses of medical research are now required by medical 
school. Therefore, current Chinese medical school graduates have the basic 
knowledge of medical research methods, including clinical trials. 
 
However, the RCT as an experimental method is new to those clinicians who 
graduated from medical school 20 years ago or more. There was subject 
discrimination in medical school which derives from Chinese culture and 
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society, with the clinical course the principal concerned of the teacher and 
students. Clinicians were expected to do their work with patients to improve 
patients’ health condition in previous times. Surgeons as a group received 
most respect among doctors, because they could perform operations and 
save a patient’s life, even in the war they could join the army immediately.  
Surgeons are followed in prestige by physicians, who are considered as highly 
skilled people who could help patients in daily life, old (that means 
experienced) physicians also may be particularly admired by patients.  These 
groups are followed in prestige by the third kind of people who work in 
hospitals but do not conduct clinical jobs, such as epidemiologists or medical 
statisticians.  
 
Non-clinical students are still the group of students with lowest entry scores in 
medical school. Therefore it is hard to say this discrimination has disappeared 
totally. Another reflection of this discrimination is the difference in incomes. 
Due to the direct link between clinical work and financial income, Surgeons 
have the most opportunity to receive grey income, because they would be the 
direct person to make effect on patients’ bodies. The term grey ‘income’ was 
coined in China after 1978 when the country implemented its policy of reform 
and opening-up. It describes the significant portion of urban residents' income 
that is outside the scope of state supervision and control. Second come 
physicians, but not epidemiologist or statisticians. Therefore, those people 
who are potentially skilled in research design and research conduction do not 
work in hospitals, and thus could not help professional clinicians when 
conducting research work. 
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Summary 
In this chapter I introduced randomized controlled trial and all of its essential 
items, which are the theoretical principles of this thesis. In chapter 2 and 3, I 
will evaluate the quality of Chinese RCT publication and compare with leading 
WesternWestern medical journals and Indian medical journals on the basis of 
these principal items. In chapter 4 and 5, I will try to explain the reason of 
difference from RCT stakeholders: Chinese clinicians and patients, by 
presenting the fieldwork result. In chapter 6, I will review 2008-09 Chinese 
RCT and compared with previous research, in order to see any change on 
Chinese RCT publication quality. In chapter 7, I will explore the intension of 
Chinese clinicians and patients’ behaviours through multi-aspect. 
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Chapter 2. An assessment of the quality of 
randomized controlled trial conducted in China in 
2004 and an updated assessment on 2008-09 
 
Outline 
In this chapter, I conduct a systematic review largely derived from the 
CONSORT statement, to evaluate the quality of main published Chinese 
RCTs.  I found the quality of Chinese published RCTs needs to improve in 
many items.  
 
China is a developing country with the biggest population of any country in the 
world.  Research in China has been rapidly gaining momentum, but as yet 
there has been no systematic evaluation of the current standard of trials 
conducted there.  Evaluations of the quality of Chinese RCTs have been 
restricted to a few selected journals and a limited list of quality indicators44-46 .  
For example, a recently published systematic review of the effectiveness of 
hyperbaric oxygen using Chinese RCTs found that the published papers 
reported inadequate information and were generally of poor quality.47  
 
I present a critical evaluation of randomised controlled trials conducted in 
China and published in 2004.  My aim was to infer the general level of 
research in China and make suggestions for improvements in the design, 
conduct and reporting of Chinese RCTs.  
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2.1 METHODS 
2.1.1 Search strategy 
Search strategy 
Randomised controlled trials published in 2004 were identified through two 
broad sources: 
1. Using the PubMed database. PubMed includes MEDLINE and 
OLDMEDLINE48 but papers published in many non-English Journals are not 
listed. I searched PubMed for Chinese randomised controlled trials published 
in 2004 using the textwords 'chin*' and the PubMed filter for randomised 
controlled trials. 
2. Since many of the main medical journals in China are not indexed in 
PubMed, or in any electronic database, I also accessed the online versions of 
each journal in the Journal Series of the Chinese Medical Association. The 
Journal Series of the Chinese Medical Association includes 71 journals, which 
comprise the main core medical journals in Mainland China and additionally 
the Chinese version of the British Medical Journal. 
I used the same search strategy as we used for our previous study 
 
For both sources, reference lists of included studies were checked. No 
language or other limitations were imposed. I translated Chinese text into 
English, and another Chinese author helped me in some cases. Titles were 
initially scanned for relevance and abstracts read if titles were unclear. The full 
text of papers with no abstract was viewed and checked for eligibility. 
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2.1.2 Inclusion and exclusion criteria 
 
I included any papers reporting randomised controlled trials on all disease 
groups and all types of interventions, which were published in 2004, took 
place in China and included Chinese citizens. I excluded reports that did not 
include any participants from Mainland China. I excluded papers from Hong 
Kong and Taiwan where research and clinical practice may be different from 
those from the Mainland. 
Same inclusion and exclusion criteria were applied on the research of 2008-
09. 
 
 
 
2.1.3 Assessment of quality 
 
The quality of each trial was assessed using a standard checklist based on 
the CONSORT statement, an internationally agreed standard for reporting 
RCTs.11  I also added some customised indicators in order to extract further 
information specific to the Chinese papers.  I did not use overall quality scores 
or categories to judge each paper because the use of summary scores is 
known to be problematic and often obscures individual aspects of quality.49   
 
 
 
                                                                                                                              - 25 - 
 
Table 2.1. Indicators used to describe and evaluate included randomised controlled 
trials 
Indicator Description 
Descriptive indicators 
1 Publication language Chinese or English 
2 Nationality of authors Chinese, international or collaboration 
3 Funding source As reported 
4 Disease area Simple categories 
5 Choice of comparator 
interventions 
Placebo/alternative treatment/no treatment 
6 Size of trial Number of participants 
7 Ethical committee 
approval 
Yes/No 
8 Informed consent from 
participants 
As reported 
Quality of reporting: CONSORT indicators 
9 Sample size How was sample size determined? 
10 Randomisation Was the trial randomised? 
11 Allocation concealment What method was used to implement the random 
allocation sequence? 
12 Blinding Whether or not patients and/or investigators were 
blinded to group assignment 
13 Baseline characteristics Were the baseline demographic and clinical 
characteristics of each group reported 
14 Primary outcomes Did they report which outcome was designated as 
the primary outcome? 
15 Length of follow-up As reported 
16 Loss to follow-up As reported 
17 Statistical reporting Were confidence intervals or p values reported to 
indicate precision? 
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2.1.4 Data extraction and analysis 
One reviewer extracted data from all included papers. A second reviewer 
independently checked a random sample of 26% of the papers. Discrepancies 
were resolved where possible by discussion, and the sample results 
compared with the full results using Kappa scores. Data on the quality of the 
included papers were presented in tabular format accompanied by a critical 
description. 
 
 
2.2 RESULTS  
2.2.1 Search results 
 
Figure 2.1 describes the results of the search and the identification of eligible 
trials.  Among 372 identified papers 29 papers were initially excluded as they 
were duplicate publications. Of the remaining 343 studies 307 (89%) clearly 
described that their patients were allocated randomly to treatments and 
therefore were included as confirmed RCTs.  Thirty-six studies were excluded 
as they either were not, or could not be confirmed as, RCTs (table 2.2).   
 
 
271 papers were identified from Pubmed and 104 papers were from journal 
series of the Chinese medical association. 25 duplicate papers were excluded, 
108 papers were excluded on the basis of the abstract. 242 papers were 
included in the study. (figure2.2.) 
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Figure 2.1. Flow chart of selection decisions of 2004 
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Figure 2.2. Flow chart of selection decisions of 2008-09 
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Table 2.2 Reasons for excluding papers 
Reason for exclusion 
Number of 
papers 
Before/after studies  17 
 Brief report given only 6 
 Case control study 5 
 No control arm 4 
Randomisation not mentioned in full 
text  
2 
 Allocated by patients’ choice 1 
 Allocated by patients’ economic status 1 
 Total 36 
 
 
2.2.2 Agreement between reviewers 
 
Agreement between the reviewers was good with a kappa score of greater 
than 0.7 for the main indicators (Funding source 0.73, disease area 0.8, 
choice of comparator interventions 0.75, ethical committee approval 0.72, 
informed consent from participants 0.73, sample size 0.86, randomisation 
0.76, allocation concealment 0.78, blinding 0.75, baseline characteristics 0.75, 
primary outcomes 0.8, loss to follow-up0.6, length of follow-up 0.62, statistical 
reporting 0.71) 
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2.2.3 Characteristics of the included trials in 2004 
2.2.3.1  Publication language 
Of the 307 included RCT papers, 259 (84%) were written in Chinese. The 
remaining 48 papers were published in English. 
 
2.2.3.2  Nationality of authors 
292 (95%) included papers were written by authors based in Chinese 
research institutes; the remaining papers were collaborations between 
Chinese and foreign researchers. There were no trials conducted or reported 
only by foreign researchers. 
 
2.2.3.3  Funding source 
Of the 307 papers, 232 (75.6%) did not report their sources of funding. 
Funding was from provincial/municipal and national sources in 38 trials 
(12.4%) and 23 trials (7.2%) respectively. Foreign pharmaceutical companies, 
universities, international research agencies and the military financed five or 
fewer trials each. 
 
2.2.3.4  Disease area 
Fifty (16.3%) of the RCTs focused on diseases of the digestive system (Table 
3). The second most published disease area was disease of the circulatory 
system with 48 papers (15.6%), followed by tumours with 42 papers (13.7%) 
and diseases of the urogenitary system (37 papers (12.1%)). Central nervous 
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system, motor system and respiratory system diseases each had 
approximately 5% share of the total number of trials as did the category of 
primary prevention or health promotion. One hundred and twenty-two of the 
included papers (39.7%) reported studies of traditional Chinese treatments 
such as traditional Chinese medicine (TCM), massage and acupuncture. 
 
Table 2.3 Disease area of included trials 
Disease area Number of papers Percent 
Digestive system diseases 50 16.3 
Circulatory system diseases 48 15.6 
Tumours* 42 13.7 
Urogenital system diseases 37 12.1 
Nervous system diseases 16 5.2 
Motor system diseases 16 5.2 
Healthy population 15 4.9 
Respiratory system diseases 15 4.9 
Endocrine system diseases 12 3.9 
Immune system diseases 9 2.9 
Others 47 15.3 
Total 307 100 
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2.2.3.5 Choice of comparator interventions 
Thirty-nine (12.7%) of the included trials compared active treatment with a 
placebo group. Three of these were randomised controlled crossover trials 
where participants were blinded to the order of drug taken. In 179 (58.3%) 
trials the new treatment being tested was compared with an alternative active 
treatment, and in 79 (25.7%) trials the new treatment was compared with a 
treatment described as the "standard", but with no specific details. Seven 
additional studies included a control group receiving no treatment: three of 
them were health education and promotion projects, two of them were health 
rehabilitation and two drug trials. A further three papers described trials with 
three different treatment arms: active treatment, standard treatment and no 
treatment. 
2.2.3.6 Size of the trials 
The number of participants in each included trial ranged from 3 to 19200, with 
a median of 78. 
2.2.3.7&8 Ethical issues (Ethics Committee Approval and Informed 
Consent) 
Only 33 (10.8%) of the included Chinese trials reported approval by an ethics 
committee. The majority of the study reports (249 or 81%) did not provide any 
information about informed consent although 54 (17.6%) of papers stated that 
the participants did give consent. The remaining four studies stated that 
participants were included in the trial of their own free will. 
2.2.3.9 Sample size 
Only nine (2.9%) of the 307 papers mentioned sample size calculation. 
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2.2.3.10&11  Methods of randomisation & allocation concealment 
 
 
Table 2.4 Methods of randomisation 
Methods of randomisation 
Number of 
papers (%) 
Not clear 199 (64.8%) 
 Random number sheet 73 (23.8%) 
 Random allocation card 13 (4.2%) 
 Sealed envelope 11 (3.6%) 
 Computer allocation 7 (2.3%) 
 Toss of a coin 4 (1.3%) 
 Total 307 (100%) 
 
In nearly two-thirds of the included trials (Table 2.4) the authors failed to 
report details of their methods of randomisation. Seventy-three (23.8%) of the 
trials reported using a random number table to allocate participants; 13 (4.2%) 
a random allocation card; 11 (3.6%) a sealed envelope; 7 (2.3%) computer 
allocation and 4 (1.3%) the toss of a coin. Twenty-four trials allocated 
participants using visit order that were included in the "not clear" group. No 
trial mentioned allocation concealment. 
2.2.3.12  Blinding 
254 (82.7%) papers provided no information about blinding of either 
participants or investigators. In 39 (12.7%) trials, both the investigators and 
participants were blinded. In 9 (2.9%) trials the participants were not blind, 
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and in 5 (1.6%) the investigators were not blinded to the participants' 
treatments. 
2.2.3.13. Reporting of baseline characteristics 
Eighty-nine (29%) of the included papers fully reported the baseline 
characteristics of the participants in a separate table. Two hundred and nine 
(67%) of the papers described baseline characteristics using either text or 
mixed tables, which also included results. In 9 papers (2.9%) only age was 
given in the baseline information, and in two papers no information was given 
other than a statement that the baseline characteristics matched in both arms. 
2.2.3.14. Reporting of primary outcomes 
Only 11 (3.6%) of the included trials indicated which measure was used as the 
primary outcome; the remainder merely reported a list of results from which it 
was not possible to distinguish which outcome was the primary. 
2.2.3.15. Length of follow-up 
Table 2.5 Length of follow up of included RCTs (days) 
 Days of follow-up 
Number of papers 
(%) 
Not clear 105 (34.2%) 
 0-30 85 (27.7%) 
 31-90 43 (14.0%) 
 91-365 43 (14.0%) 
 366-3650 31 (10.1%) 
 Total 307 (100.0%) 
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Table 2.5 details the distribution of length-of-follow-up for participants in the 
included studies. In 105 (34.2%) of papers, there was no information about 
the length of time for which participants were followed. The mean length of 
follow-up (where stated) was 166 days, although the median (interquartile 
range) was 56 (8 to 360) days. 
 
2.2.3.16. Loss-to-follow-up 
 
Table 2.6    Dropout rate of included trials 
 Dropout rate (%) 
Number of 
papers Percent 
Cumulative 
Percent 
0 165 53.7 53.7 
less than 5% 32 10.4 64.1 
> 5% but < 10% 23 7.5 71.6 
 >10% but < 25% 18 5.9 77.5 
More than 25% 12 3.9 81.4 
 Not clear 57 18.6 100.0 
 Total 307 100.0  
 
Over half of the trials (165 studies – 53.7%) reported that no participants had 
dropped out (Table 2.6). Sixty-four percent of all the clinical trials showed a 
drop out rate of 5% or less by the end of the study, and overall 70% of all the 
trials had a drop out rate lower than 10%. Fifty-seven (18.6%) studies failed to 
report dropout rates. 
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2.2.3.17. Statistical reporting 
The majority of the papers (298 trials or 97.1%) conducted and reported test 
for statistical precision rather than calculating and reporting confidence 
intervals. In only 20 papers (6.5%) did the authors use confidence intervals to 
describe the uncertainty around their estimates? 
2.2.3.18 Subgroup analysis 
The main quality indicators of trials included double blinding, allocation 
concealment, report of primary outcome, ethical approval and informed 
consent. In the subgroup analysis I explored the differences in trials quality 
and their associations with individual trials’ characteristics.  
Publication language 
Of the 307 included RCT papers, 259 (84%) were written in Chinese. The 
remaining 48 papers were published in English. 
Chi-square tests were used. There are significant differences on double 
blinding, type of treatment, ethical approval and informed consent between 
different publication languages.  
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Table 2.7 Statistical analysis for publication language associated to RCT 
papers characteristics 
 
*OR= 1 means compared with papers published in English, Chinese RCT papers have 
the same rate on reporting those characteristics. 
OR > 1 showed that Chinese papers denoted a lower rate of reporting those 
characteristics, with worse quality. 
 
 
 
 
 
 
 RCT papers characteristics 
 Double 
blinding 
Traditional 
Chinese 
treatment 
Primary 
outcome 
Ethical 
committee 
approval  
Informed 
consent 
Chi-square 10.85 17.6 3.7 20.11 79.1 
P value 0.002 <0.0001 0.054 <0.0001 <0.0001 
OR 3.26 0.18 2.7 5.2 16.4 
95% CI 1.57-6.80 0.07-0.43 0.92-11.68 2.39-11.36 7.9-33.3 
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? Authorship 
Of the 307 included RCTs, 292 (95%) were written by authors based in 
Chinese research institutes; the remaining papers were collaborations 
between Chinese and foreign researchers.  There were no trials conducted or 
reported only by foreign researchers. 
There are significant difference between different author ship on double 
blinding, type of treatment, ethical approval and informed consents.  
 
Table 2.8 Statistical analysis for authorship associated to RCT papers 
characteristics 
 
 
 RCT papers characteristics 
 Double 
blinding 
Traditional 
Chinese 
treatment 
Primary 
outcome 
Ethical 
committee 
approval  
Informed 
consent 
Chi-square 13.96 4.59 0.43 4.16 62.4 
P value 0.0002 0.032 0.51 0.04 <0.0001 
OR 0.16 4.5 2 0.30 0.01 
95% CI 0.06-0.47 1.0-20.4 0.24-20 0.09-1.02 0.001-0.09
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*OR= 1 means compared with papers written by Chinese authors, combined authors’ 
RCT papers have the samrate on reporting those characteristics. 
OR < 1 showed that combined authorship denoted a higher rate of reporting those 
characteristics, with good quality. 
? Size of the trials 
The number of participants in each included trial ranged from 3 to 19200, with 
a median of 78. 
In statistical analysis, Trials were allocated to 5 different groups for the trials 
size: 3- 100, 101-500, 501-1000, 1001-5000, 5001-19200, There are 
significant differences among different trial size groups on primary outcome 
and ethical committee approval. 
 
Table 2.9 Statistical analyses for trial size associated to RCT papers 
characteristics 
 
 
 RCT papers characteristics 
 Double 
blinding 
Traditional 
Chinese 
treatment 
Primary 
outcome 
Ethical 
committee 
approval  
Informed 
consent 
Chi-square 7.2 6.75 13.33 22.6 6.4 
P value 0.12 0.15 0.01 <0.0001 0.16 
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? Western vs. traditional Chinese medicine 
One hundred and twenty-two trials were about traditional Chinese medicine, 
the rest 185 were about Western medicine. There was significant difference 
on report of double blinding, primary outcome, ethical committee approval and 
informed consent. 
 
 
 
 
Table 2.10 Statistical analyses for different treatments associated to RCT 
papers characteristics 
 
RCT papers characteristics 
 Double 
blinding 
Primary 
outcome 
Ethical 
committee 
approval  
Informed 
consent 
Chi-square 9.32 7.5 11.7 22.4 
P value 0.002 0.006 0.001 <0.0001 
OR 3.3 1.06 5.49 7.1 
95% CI 1.49-7.7 1.03-1.1 1.89-16.1 2.78-16.6 
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*OR= 1 means compared with those about Western treatment papers, traditional 
Chinese papers have the same effect size on reporting those characteristics. 
OR > 1 showed that traditional Chinese treatment papers denoted a lower rate of 
reporting, those characteristics, with worse quality. 
 
 
? Pubmed vs Non-Pubmed 
Two hundred and thirty-nine trials were included from Pubmed, the rest 68 
were from Journal series of Chinese Medical Association. There are 
significant difference between Pubmed and non-Pubmed papers on report of 
double blinding and informed consent.  
Table 2.11 Statistical analyses for Pubmed papers associated to RCT papers 
characteristics 
RCT papers characteristics 
 Double 
blinding 
Traditional 
Chinese 
treatment 
Primary 
outcome 
Ethical 
committee 
approval  
Informed 
consent 
Chi-square 4.7 3.84 0.1 3.65 8.26 
P value 0.03 0.051 0.74 0.056 0.004 
OR 0.32 0.58 0.77 0.31 0.25 
95% CI 1.07-9.06 0.33-1.0 0.16-3.67 0.91-10.5 1.47-12.18
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OR= 1 means compared with Pubmed papers, Non-Pubmed papers have the same rate 
on reporting those characteristics. 
OR < 1 showed that Pubmed papers denoted a higher rate of reporting those 
characteristics, with good quality. 
 
2.2.4 Characteristics of the included trials of 2008-09 
2.2.4.1 Publication language  
Of the 242 included RCT paper, 148 (61%) were written in Chinese. The 
remaining 94 (39%) were written in English.  
 
2.2.4.2 Funding source 
Of the 242 paper, 149 (62%) did not report their source of funding. funding 
was from provincial/municipal and national source in 42 (17%) trials and 36 
(15%) trials respectively. The pharmaceutical industry funded 8 (3%) trials, 
international research agencies funded four trials and universities funded 
three trials. 
 
2.2.4.3 Disease Area  
Sixty-four (26.5%) of the RCTs focused on diseases of the circulatory system. 
Motor system disease was the second most commonly represented disease 
with 32 trial reports (13.2%), followed by urogenital system disease with 26 
papers (10.7%), digestive system disease 25 papers (10.3%), oncology with 
24 papers (9.9%) and nervous system diseases with 15 papers (6.2%). 
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Papers reporting trials concerned with the respiratory system, endocrine 
system, immune system disease and primary prevention or health education 
each had approximately 5% share of trials.  
 
 
 
 
Table 2.12 Disease area of include trials 
Disease area Number of papers percent 
Circulatory system 
disease 
64 26.5 
Motor system disease 32 13.2 
Urogenital system 26 10.7 
Digestive system 
disease 
25 10.3 
Tumours  24 9.9 
Nervous system disease 15 6.2 
Healthy population 12 5.0 
Respiratory system 
disease 
10 4.1 
Endocrine system 
disease 
6 2.5 
Immune system disease 6 2.5 
Others  22 9.1 
Total  242 100 
                                                                                                                              - 44 - 
2.2.4.4 Size of trials 
The number of participants in each included trial ranged from 9 to 30283, with 
a median of 80. 
 
 
2.2.4.5&6. Ethical committee approval and informed consent 
Of the 242 paper, 107 reported approval by ethical committee, 133 reported 
they have participators’ informed consent for the trial.  
 
Quality of reporting  
 
2.2.4.7. Methods of Randomisation 
 
Table 2.13 Methods of Randomisation 
Method Number of papers (%) 
Not clear 139(57.4%) 
Random number table 39(16.1%) 
Patient visit order 29(12.0%) 
Computer allocation 24(9.9%) 
Sealed envelop 7(2.9%) 
Toss coin 4(1.6%) 
Total  242 (100%) 
 
One hundred and thirty-nine (57.4%) papers failed to report the method of 
method of randomisation. 39 (16.1%) of the trials reported using random 
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number table to allocate participants, 29 (12.0%) patients visiting order, 24 
(9.9%) computer allocation, 7 (2.9%) sealed envelop and 4 (1.6%) toss coin.  
 
 
 
2.2.4.8. Blinding  
One hundred and seventy-five (72.3%) papers provided no information about 
blinding of either participants or investigators. 29 (12.0%) papers reported 
they did double blind in their trial. 18 (7.4%) papers reported they did single 
blind. The remaining 20 papers reported they were open trials. 
 
2.2.4.9. Allocation Concealment 
Of 242 included paper, 11(4.6%) mentioned they used allocation concealment 
clearly in text. 24(9.9%) trials allocated participators by computer and 39 
(16.1%) by random number table, but they did not have a clear statement of 
using them as allocation concealment. 
 
2.2.4.10. Reporting of baseline characteristics 
One hundred and sixty-two (66.9%) of the included papers reported the 
baseline characteristics of participators in a separate table.  48 (19.9%) 
papers describe baseline characteristics using mixed table or text. 32 (13.2%) 
papers only describe participators’ age and sex as baseline characteristics.  
 
2.2.4.11. Report of primary outcomes 
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Only 28 (11.6%) papers indicated which measurement was used as their 
primary outcome. In the remaining 214 (88.4%) trials, it is not clear which one 
(if any) was prespecified to be the primary outcome. 
 
 
 
2.2.4.12. Statistical reporting  
All the included RCTs report their statistical result by using statistical tests and 
P-values. Only 24 (9.9%) papers used confidence interval to describe the 
uncertainty around their estimates of treatment effect. 
 
 
2.2.4.13. Length of follow up  
The mean length of follow-up was 221 days, the median (interquartile range) 
was 32 days. 
 
2.2.4.14. Loss to follow up 
181 (74.8%) of include trials reported they have no participators drop out. 
82.2% of all included papers showed a drop out rate of 5% or less, and 90.1% 
of all the trials had a drop out rate lower than 10%. 
 
2.2.4.15. Intention-to-treat 
Two of 242(0.8%) of included papers described ‘intention-to-treat’ as their 
data analysis principle.  
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2.2.5 Change between 2008-09 and 2004 
I compared trials from the 2008-09 and 2004 cohorts on the main trial quality 
indicators. Compared to 2004, 2008-09 Chinese published RCTs had a 
significant improvement on their description of informed consent, ethical 
committee approval and report the reporting of a primary outcome. In 2008-09 
period, 11 (4.6%) RCTs reported they did concealment on the patient 
allocation, and 100% of the papers used P value to describe the statistical 
result from statistical tests. 
 
Table 2.14 The results comparison between 2004 and 2008-09 period 
 N=307 
number of 
reported 
(%)2004 
N=242 
number of 
reported 
(%) 2008-
09 
2008-09 
OR 
(compared 
with 2004) 
95% CI P 
Concealment 0 11(4.6%) 999 - <0.001*
Double blind 39(12.7%) 29(12.0%) 0.94 0.559-
1.566 
0.80 
Informed 
consent 
54(17.6%) 133(55.0) 4.14 3.79-
8.24 
<0.001*
Ethical 
committee 
approval 
33(10.8%) 107(44.2%) 6.36 4.1-9.87 <0.001*
Primary 
outcome 
11(3.6%) 28(11.6%) 3.52 1.71-
7.25 
0.0007*
P-Value 298(97.1%) 242(100%)   <0.01* 
Confidence 
interval 
20(6.5%) 24(9.9%) 1.58 1.18-
2.94 
0.1489 
Intention- to-
treat 
11(3.6%) 2(0.8%) 0.22 0.05-
1.03 
0.0542 
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2.2.6 Exploring Sub-groups 
Papers from 84 different journals were included in the research on journal 
quality in 2004 and 114 journals included in 2008-09.  26 journals were 
represented in both data sets. I did an additional supportive analysis on these 
26 journals, in order to examine whether there is evidence of the difference in 
reporting quality in the same journals between different periods. 
 
In this sub-group exploratory model, I also considered the individual journals 
as the random effects. I found, the report of ethical committee approval was 
improved significantly. However surprisingly, the report of double blinding and 
confidence interval was decreased significantly.  
 
The positive outcome reporting rate over time  
Through the result from non-linear mixed model, I found no evidence of 
change in the reporting of the rate of positive results from all included journals 
between different time periods. The trials from 2008-09 have the similar 
positive result rates to trials published in 2004, (OR= 1.01, 95% CI 0.81 to 
1.27, P=0.93). In the sub-group analysis of the 26 journals reporting trials in 
both time periods we also found no evidence of a reduction in the high rate of 
positive result reporting (OR=1.20, 95% CI 0.80 to 1.80, P=0.3766). 
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Table 2.15 The results comparison between 2004 and 2008-09 on 26 journals 
26 journals 2004 
N=86 
number of 
reported 
(%) 
2008/9 
N=89 
number of 
reported 
(%)  
2008-09 
OR 
(compared 
with 2004) 
95% CI P 
Concealment 0 1(1.1%)   0.9 
Double blind 18(20.9%) 5(5.6%) 0.22 0.078-
0.646 
0.0059 
Informed 
consent 
20(23.3%) 32(36.0%) 1.8526 0.947-3.62 0.0714 
Ethical 
committee 
approval 
13(15.1%) 26(29.2%) 2.317 1.087-
4.939 
0.0297 
Primary 
outcome 
6(7.0%) 1(1.1%) 0.1515 0.017323-
1.325 
0.0876 
P-Value 84(97.7%) 89(100%)   0.47 
Confidence 
interval 
11(12.8%) 3(3.4%) 0.2378 0.0628-
1.109 
0.0348 
Intention- to 
treat 
7(8.1%) 2(2.2%) 0.259 0.05118-
1.3152 
0.1026 
2.3 Discussion 
2.3.1 Key results 
The study of trial quality is rare in developing countries, and tends to focus on 
limited clinical areas50;51 . Although among Chinese publications there are a 
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few papers which describe trial quality in specific journals or fields47;52-57, this 
is the first systematic study to evaluate the quality of trial conduct and 
reporting in a sample which is likely to be more representative of Chinese 
RCTs in general. 
My review revealed that the standard of reporting of trials was generally poor, 
which concurs with the other published reports on Chinese trials47;52;55;57. For 
example, nearly two-thirds failed to report any information on their methods of 
randomisation, reinforcing previous work55;57 . In the remainder there were 
various methods of random allocation, of which about a quarter reported using 
a computer-generated method or a random number table, which are the 
usually acceptable ways of randomisation. None of the trials discussed 
allocation concealment. If the allocation of the patient is not adequate and 
fully independent of the enrolling investigator, then this may allow either 
conscious or unconscious selection of participants into the trial, or into 
particular arms of the trial, thus introducing selection bias and undermining 
randomisation. The internal validity of a randomised controlled trial has been 
shown to be directly associated with a clear description of appropriate 
methods of random allocation of participants, and concealment of their 
allocation58. 
Over 80% of trials provided no information about blinding of either participants 
or investigators. This confirms the result observed in a review of RCTs of 
traditional Chinese medicine57. Without blinding the groups may have been 
treated differently by the investigator and the outcomes not measured 
objectively, thus creating further assessment bias. Participants aware of their 
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treatment may behave differently or have particular expectations8 , thus 
affecting the results. 
Interestingly, among the included Chinese studies in this review, over half 
stated that none of their participants dropped out. This is unusual compared 
with trials in countries with more established research programmes, where a 
drop-out rate of below 5% is generally considered a very good result. Over 
60% of the trials in this review reported a drop-out rate of less than 5%, and 
two-thirds less than 10%. The reasons behind these very low rates warrant 
further investigations. 
The reporting of ethical issues was inadequate in the Chinese RCTs. Fewer 
than 11% of the trials reported having ethical committee approval, although 
the latter is a legal requirement in China59 . Also, only a minority of the 
Chinese studies (17.4%) gave adequate details about informed consent 
procedures; a few mentioned that participants attended of "their own free will" 
but the remainder made no mention of consent. However, this level appears 
better than in a recent review of traditional Chinese medicine trials57 . 
Compared with many published trials in developed countries60, the standard 
of reporting in China is lagging behind, although there are still many fields in 
Western countries which have inadequate standards of reporting61 . However, 
the application of the CONSORT statement has demonstrated benefits in 
improving reporting29 and could be expected to do the same in China. 
My review revealed that compared to our 2004 review, the ethical committee 
approval and reporting participants’ informed consent have been improved 
significantly. In 2005, the Chinese Food and Drug Administration published 
                                                                                                                              - 52 - 
the instruction of ‘Ethical requirement in conduct of randomised controlled 
trials’. In this regulation, GCP and Helsinki Deceleration were promoted as the 
basic regulation in the RCT ethical area.  This may be one of the explanations 
for the improvement on these measures. 
 
The Primary outcome in particular has much invested in it, because it is 
normally the outcome alone that indicates whether or not the trial provides 
evidence at an acceptable level that the treatment is efficacious.62  The choice 
of outcome measure is an important design consideration.. Chinese RCTs 
have significant improvement on the reporting of primary outcome between 
time periods. However, in 2008-09, only 28(11.6%) RCTs identified a primary 
outcome, which rate is still very low and undermines the trial interpretability. 
The primary outcome as an essential indictor should be presented much more 
clearly. 
 
There are several studies which concentrate on Chinese published RCT 
quality. All of them suggest that Chinese trialists should use CONSORT as 
their basic reporting check list. In order to improve overall the quality of 
published RCTs, the Chinese medical journals should take the responsibility 
to ensure that CONSORT is followed. We assess all the journals from the 
journal series of the Chinese medical association on their ‘instruction for 
authors’. Unfortunately, only one journal ‘Chinese Medial Journal’ was found 
to refer to the CONSORT statement. 
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The quality of published RCT papers in Chinese was significant different from 
those published in English, on double blinding, type of treatment ,ethical 
approval and informed consent. Authorship was significantly associated with 
double blinding, type of treatment and ethical committee approval. Traditional 
Chinese treatment RCTs are significant different with Western treatment 
RCTs on double blinding, primary outcome, ethical committee approval and 
informed consent. In addition, pubmed papers were significant different from 
non-pubmed papers on the double-blinding, and informed consent.  All of 
these results showed that Chinese RCT authors need to improve the quality of 
RCT conducting and report writing. The involvement of Western medical 
authors might also help to improve the quality of Chinese RCT reports.  
 
A paper written by Chinese Cochrane Centre published in May 2008, which is 
titled ‘Chinese authors do need CONSORT…’ the main recommendation of 
this paper is Chinese medical author should use CONSORT to improve their 
reporting of RCTs. We identified all the papers published 6 month after 
Chinese Cochrane Centre’s publication. However, the quality of reporting of 
RCTs is still at an unsatisfactory level.  It is clear that Chinese medial journals 
were not taking advice from medical researchers and the CONSORT 
statement has not been accepted in practice.  
 
2.3.2 Strengths of this study 
My research is a prospective study of the quality of published Chinese RCTs.  
I used the same search strategies to search the same data resources, and 
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therefore the difference from search strategies is decrease to minimum. The 
difference is from all the included journals individually.  
 
2.3.3 Limitations 
Although I undertook a thorough search for eligible studies using both 
PubMed and the Journal Series of the Chinese Medical Association, I may 
have missed relevant studies not included in the databases. The Journal 
Series of 71 Chinese journals comprises the core of the Chinese medical 
journals, but only approximately 20% of the total. RCTs which were not 
described as such in the abstract would have been excluded; however it is not 
clear how many such false negatives there would have been. Indeed failure to 
mention correctly the study design in the abstract is a mark of poor quality. 
My research for Chinese Trials through Pubmend and Journals Series of the 
Chinese Medical Association may have included journals which are 
unrepresentative of all Chinese journals, although because of our research 
strategy these may be considered the highest status journals publishing the 
most influential trials reports.  
 
 
2.4 Conclusion 
Reporting of RCTs in China requires substantial improvement to meet the 
targets of the CONSORT statement. The conduct of Chinese RCTs cannot be 
directly inferred from the standard of reporting; however without good 
                                                                                                                              - 55 - 
reporting the methods of the trials cannot be clearly ascertained. Research 
bodies in China should ensure that the reporting of RCTs is improved to meet 
internationally agreed standards, thereby allowing the conduct of their studies 
to be monitored and encouraging high quality standards. Ethical committee 
approval and reporting of participants’ informed consent have been improved 
significantly in 2008-09. However, reporting of RCTs in China needs 
substantial improvement to meet the target of the CONSORT statement. 
 
 
Summary 
In this chapter, I reviewed all published Chinese RCTs of 2004, and find 
Chinese RCT publications need to be improved in many items of CONSORT 
statement. In chapter 3, I will compare Chinese RCT publications with 
Western leading medical journals and Indian medical journals, in order to 
locate the status of Chinese RCT research in world medical society. I also 
evaluated Chinese updated published RCT papers by using the same 
evaluation strategy, and made comparison with my previous research. 
Although there are significant improvements in some indicators, the quality of 
Chinese published RCT still need substantial improvement. In addition, the 
positive result rate remained as high as it was in 2004. 
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Chapter 3. Are Randomized Trials Conducted in China 
or India biased?  A comparative empirical analysis 
 
 Outline 
In this chapter, I make comparisons between Chinese, Indian and a 
contemporaneous ‘gold standard’ sample of Western RCT publications, in 
order to develop an understanding of the status of Chinese RCT publications 
among the world medical research area. 
 
China and India are the two potentially important countries undertaking RCTs 
given their substantial populations. They are also potentially important users 
of the results of high quality trials.  As well as investigator led trials, the 
international pharmaceutical and device industries increasingly conduct their 
development programmes for new products in lower income countries.  
Therefore, trial quality in low-income countries affects not only the substantial 
local population but also potentially influences health policy in other regions. 
In this thesis I examine aspects of the quality of the reports of trials conducted 
in China, and contrast these with India and a “gold standard” set of trials 
conducted in Europe and North America.  A better understanding of the 
quality of trials is important both to aid current interpretation but also to inform 
any future methodological work on the quality of RCTs in those countries.  
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I present a critical evaluation of randomized controlled trials conducted in 
China and published in 2004.  The aim was to appraise the general level of 
research in China and make suggestions for improvements in the design, 
conduct and reporting of Chinese RCTs. Furthermore, I examine whether 
published reports of Chinese or Indian trials exhibit a high proportion of 
positive results compared to a “gold standard” selection from high quality 
European and North American journals.  I also examine the extent to which 
any difference in the rate of positive results in trials may be due to trials 
examining traditional Chinese medicine treatments which form a particular 
subject of investigation in Chinese trials, or whether it may be due to markers 
of trial quality.  
 
3.1 Method 
 
3.1.1 Derivation of study material 
 
Relevant Indian papers were identified through PubMed,and 'ISI Web of 
Sciences' databases. PubMed includes MEDLINE and OLDMEDLINE48 but 
many non-English Journals are not listed. I searched Pubmed for Indian 
randomised controlled trials published in 2004 using the textwords ‘india*’ and 
the PubMed filter for randomised controlled trials. No language or other 
limitations were imposed.  
 
Relevant Western papers were also identified though Pubmed, where the 
search was limited to six journals: JAMA, BMJ, New England Journal of 
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Medicine, Annals of Internal Medicine, Lancet and Circulation. (Circulation 
was selected because of the following reasons: Cardiac & Cardiovascular 
system disease is the top 1 health killer in Western population. Impact factor 
of circulation is 12.755- Ranks #1 among journals in the Cardiac & 
Cardiovascular Systems category, #1 among journals in the Haematology 
category, and #1 among journals in the Peripheral Vascular Disease category.) 
  
 I used the Pubmed filter for randomised controlled trials to identify RCT 
publications in 2004. That year was selected because I already had 
comparable data from China from conducting a systematic review of Chinese 
RCT papers published in 2004. In order to have similar number of Western 
RCT papers as Chinese or Indian ones, I reviewed the 2nd, 3rd and 4th 
issues of each month, if they published weekly. For ‘Annals of Internal 
Medicine’ which publishes bimonthly, I reviewed the 2nd issue of each month.  
 
 
3.1.2 Inclusion and exclusion criteria 
 
I included full reports of randomised controlled trials on all disease groups and 
all types of interventions. For Chinese papers, I excluded reports that did not 
include any patients from Mainland China. I excluded papers from Hong Kong 
and Taiwan as they are under the jurisdiction of independent governments 
with separate medical budgets and thus may not be representative of 
Mainland China. Papers published in Indian journals were excluded if they did 
not include any Indian patients. 
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3.1.3 Assessment of quality 
The quality of each trial was assessed using a checklist derived from the 
items included in the CONSORT statement, an internationally agreed 
standard for reporting RCTs. I added some further items in order to extract 
further information specific to my research papers.  
 
 
3.1.4 Outcome measures 
I derived the ‘positive outcome rate’ from each included trial to describe the 
potential for bias. The positive outcome rate was defined as the number of 
outcomes reported to have a statistically significant result divided by the total 
number of outcomes reported for the trial. Apart from the potential 
confounding effect of Chinese medicine trials (which I hypothesised could 
have systematically different treatment effects) I did not identify potential 
systematic confounding factors at the level of the country a priori.  However I 
did recognise that a systematic difference in the mix of disease areas 
investigated (analogous to the concerns about Chinese Medicines) might lead 
to an apparent difference between regions (eg China, India, or Western).  
These were explored in supportive analyses. 
 
3.1.5 Statistical analysis 
Comparative rates of quality indicators were summarised by country, and 
differences between countries on these scores were assessed using Chi 
Squared tests.  I used non-linear mixed models with a logit link and binomial / 
normal error to examine the effect of country on the rate (r/n) of positive 
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results as a proportion of all outcomes reported in clinical trials.  In the 
principal analysis I examined the effect of country, and defined the individual 
trials as random effects, thus accounting for study level differences (extra 
binomial variability)63. Further potential confounders (eg disease area, 
industry sponsorship, double blinding, concealment of allocation, and the 
‘intent to treat’ principle) were prespecified to be considered in an additional 
exploratory analyses, to identify a parsimonious model in which candidate 
variables were selected for final inclusion on the basis of backward selection, 
with an α level for inclusion of he model of .05.  Multivariable analyses were 
conducted using the statistical package SAS (SAS Institute, Cary, NC).  
 
3.2 Results 
 
Among 372 identified Chinese papers 29 papers were initially excluded as 
they were duplicate publications. Of the remaining 343 studies 307 clearly 
described that their patients were allocated randomly to treatments and 
therefore were included.  Thirty-six studies were excluded as they either were 
not, or could not be confirmed to be, RCTs.  
 
My search for Indian Trials revealed 340 reports, identified by the use of the 
key term ‘India*’.  Of these, 124 papers were not Indian trials, 20 papers were 
brief reports or short communications and full-text was not available for 79 
papers. As a result, 117 Indian papers were included. 
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I identified 310 Western papers; six of them were brief reports, which were 
excluded from my final database, leaving a total of 304 papers. 
 
239 Chinese RCT papers were selected from Pubmed, all 117 Indian papers 
and 304 Western papers were selected from Pubmed. 
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Table 3.1. Indicators used to describe and evaluate included randomised 
controlled trials 
Indicator Description 
Quality of reporting: CONSORT indicators 
1 Allocation 
concealment 
What method was used to implement the 
random allocation sequence? 
2 Blinding Whether or not patients and/or 
investigators were blinded to group 
assignment 
3 Primary outcomes Did they report which outcome was 
designated as the primary outcome? 
4 Statistical reporting Were confidence intervals reported to 
indicate precision? 
Descriptive indicators 
5 Intent- to-treat Did they describe ‘intent to treat’ as their 
data analysis principle? 
6 Kind of treatment Whether it is traditional Chinese 
treatment? 
7 Funding source Whether it is sponsored by industry? 
8 Ethical committee 
approval 
Yes/No 
9 Informed consent 
from participants 
Yes/No 
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3.2.1. Allocation concealment 
None of Chinese RCT publications described ‘allocation concealment’ in the 
trial reports and only 1 Indian paper mentioned it; 132 of 304 (43%) Western 
papers described concealment of allocation clearly in their study reports (P < 
0.0001).  
Comparison among Pubmed papers  
None of Chinese RCT publications describe ‘allocation concealment’ in the 
trial reports. 
 
3.2.2. Blinding 
One hundred and sixty-three of 304 (54%) Western trial reports described that 
they used double blinding in their studies; while, only 39 (13%) Chinese 
papers and 40 (34%) Indian papers clearly described the use of double 
blinding in reports of their trials (P < 0.0001). However, 83% of Chinese 
papers and 61% of Indian papers were unclear in their reporting of blinding.  
Comparison among Pubmed papers  
28 (12%) of 239 Chinese papers described the use of double blinding in the 
report of their trials, compared to Indian and Western papers, P<0.0001.  
 
3.2.3. Primary outcomes 
Eleven (4%) of 307 Chinese and 14 (12%) of 117 Indian papers specified a 
primary outcome, 268 (88%) of Western papers specified a primary outcome 
(P < 0.0001).  
Comparison among Pubmed papers 
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Eight (3%) of 239 Chinese papers specified primary outcome, compared to 
Indian and Western papers, P<0.0001. 
 
3.2.4. Statistical reporting 
Twenty (7%) of Chinese papers and 19(16%) of Indian papers reported 
confidence intervals, 251(83%) of Western papers reported confidence 
intervals (P < 0.0001).   
Comparison among Pubmed papers 
Sixteen (7%) of Chinese papers reported confidence interval, compared to 
Indian and Western papers, P<0.0001. 
 
3.2.5. Intention-to-treat 
Eleven of 307 (3.6%) Chinese and 44 Indian trials (38%) described ‘intention 
to treat’ as their data analysis principle, while 238 of 304 (78.3%) Western 
trials described it as their principle (P < 0.0001).  
Comparison among Pubmed papers 
Eight (3%) of 239 chinese trials described ‘intention to treat’, compared to 
Indian and Western papers, P<0.0001. 
 
3.2.6. Type of treatment 
One hundred and twenty-two (39.7%) Chinese papers described a Chinese 
treatment trial, such as Chinese traditional medicine, acupuncture or other 
kind of traditional therapy. None of the Western and Indian trial reports 
described Chinese treatment. 
Comparison among Pubmed papers 
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Ninety-three (38%) of 239 Chinese papers described Chinese treatment. 
 
3.2.7. Funding source 
Seventy-eight of 304 (25.7%) Western trial reports described receiving 
support from industry funding; only 5 (2%) Chinese and 5 (4%) Indian trial 
reports stated that they received industry funding (P < 0.0001).  However, 232 
(75.6%) of 307 Chinese papers and 99 (85%) of 117 Indian papers did not 
report their funding source.  
Comparison among Pubmed papers 
Five (2%) of 239 Chinese papers reported they received industry fundings, 
compared to Indian and Western papers, P<0.0001. 
 
3.2.8. Ethical approval 
Thirty-three (11%) of Chinese and 91 (77%) Indian papers reported they had 
gained ethical committee approval, 296 (97%) of Western trial reports stated 
that they had received ethical committee approval (P < 0.0001). 
Comparison among Pubmed papers 
Twenty (8%) of Chinese papers reported they had gained ethical committee 
approval, compared to Indian and Western papers, P<0.0001 
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3.2.9. Informed consent from participants 
Fifth-four (18%) of Chinese papers and 93 (79%) of Indian papers stated that 
the participants provided their consent. 291(96%) of Western papers reported 
they had gained participant’s signed consent (P < 0.0001). 
Comparison among Pubmed papers 
Thirty-five (15%) of Chinese papers reported they had participant’s informed 
consent, compared to Indian and Western papers, P<0.0001  
 
 
There were substantial differences in numbers of outcomes reported in 
different studies by country (Table 3.2).  The mean outcomes reported for 
Western papers and Indian papers were 15.79 and 15.09; for Chinese papers 
the mean was 4.13. The median number of Western and Indian papers were 
12 and 8 respectively; The Chinese median number of outcomes reported 
was 3. 
 
 
Table 3.2. Number of papers’ outcomes by paper derivations    
 Median number of 
reported outcomes 
Range 
Western 12 2 to 85 
Chinese  3 1 to19 
Indian  8 2 to 74 
 
Comparison among Pubmed papers 
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The median number of reported outcome of Chinese papers was 4, range was 
from 2 to 19. 
Table 3.3. Number of papers’ outcomes by paper derivations of Pubmed 
papers    
 Median number of 
reported outcomes 
Range 
Western 12 2 to 85 
Chinese  4 2 to19 
Indian  8 2 to 74 
 
 
 
 
Table 3.4. Univariate effect analysis of potential predictors 
Predictor Odd ratio (95 %CI), P-Value 
Chinese 
Indian 
Western 
3.70 (2.89 to 4.74) P<0.0001
0.92 (0.69 to 1.24) P=0.59 
1 
Traditional Chinese treatment 4.28 (3.02 to6.06) P<0.0001 
Double blinding 0.65 (0.51 to 0.82) P=0.0004
Whether concealment 0.56  (0.42 to 0.74) P<0.0001
 
*OR=1 means compared with Western papers, Chinese papers have same 
effect size on presenting positive result rate. 
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ˆOR=1means compared with Western papers, Indian papers have the same 
effect size on presenting positive result rate. 
˜OR=1 means among all reviewed papers (Western, Chinese and Indian 
papaers), compared with Western treatment papers, traditional Chinese 
treatment papers have the same effect size on presenting positive result rate. 
°OR=1 means among all reviewed papers (Western, Chinese and Indian 
papers), compared with non-double blinding papers, double blinding papers 
have the same effect size on presenting positive result rate. 
˙OR=1 means among all reviewed papers (Western, Chinese and Indian 
papers), compared with non-concealment papers, dconcealment papers have 
the same effect size on presenting positive result rate. 
 
Table 3.4 reports the univariate results for each potential predictor in the 
model.  In each case a random effect describing the individual trial report was 
included in the model, with country of origin included as a three level factor.  I 
found Chinese papers substantially more likely to report statistically significant 
results (odds ratio (OR) 3.70, 95% CI 2.89 to 4.74; P<0.0001). Indian papers 
had a very similar result to Western papers (OR=0.92, 95%CI 0.69 to 1.24; 
P=0.59). Traditional Chinese treatments were also significantly more likely to 
report positive results than other treatments, although in a univariate model 
this result may be confounded by country. Because of the high rate of missing 
data I did not include funding source in univariate or subsequent multivariable 
models. Double blinding and concealment were both associated with a lower 
rate of positive results. 
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Table 3.5 Univariate effect analysis among Pubmed papers 
 
Predictor Odd ratio (95 %CI), P-Value 
Chinese 
Indian 
Western 
3.20 (2.47 to 5.69) P<0.0001
0.92 (0.69 to 1.24) P=0.59 
1 
Traditional Chinese treatment 4.02 (2.94 to6.82) P<0.0001 
Double blinding 0.64 (0.51 to 0.82) P=0.0004
Whether concealment 0.56  (0.42 to 0.74) P<0.0001
 
Chinese papers were substantially more likely to report statistically significant 
results (odds ratio (OR) 3.20, 95% CI 2.47 to 5.69; P<0.0001). Indian papers 
had a very similar result to Western papers (OR=0.92, 95%CI 0.69 to 1.24; 
P=0.59). Traditional Chinese treatments were also significantly more likely to 
report positive results than other treatments, although in a univariate model 
this result may be confounded by country. Because of the high rate of missing 
data I did not include funding source in univariate or subsequent multivariable 
models.  
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Table 3.6.Principal multivariable analysis and supportive analyses 
Predictor Model 0 Model 1 Model 2  Model 3 Model 4 
Chinese/West
ern 
2.54 
(0.79-8.21) 
P=0.1185 
2.84 
(1.59-5.08) 
P=0.0004 
3.07 
(2.11-4.46) 
P<0.0001 
3.13 
(2.20-4.46) 
P<0.0001 
2.96 
(2.23-3.94) 
P<0.0001 
Indian/ 
Western 
0.65 
(0.32-1.32) 
P=0.2295 
0.90 
(0.64-1.28) 
P=0.5682 
0.91 
(0.66-1.26) 
P=0.5839 
0.93 
(0.69-1.26) 
P=0.6492 
0.92 
(0.69-1.24) 
P=0.5906 
Chinese 
treatment 
0.93 
(0.16-5.54) 
P=0.9398 
2.10 
(0.65-6.74) 
P=0.2137 
1.82 
(1.22-2.72) 
P=0.0035 
1.82 
(1.22-2.72) 
P=0.0035 
1.81 
(1.21-2.7) 
P=0.0038 
Intention to 
treat 
0.84 
(0.56-1.26) 
P=0.4053 
1.07 
(0.78-1.47) 
P=0.6725 
1.08 
(0.81-1.44) 
P=0.5935 
1.08 
(0.81-1.44) 
P=0.5980 
 
Whether 
Concealment 
0.95 
(0.67-1.35) 
P=0.7848 
0.96 
(0.69-1.35) 
P=0.8252 
0.95 
(0.70-1.29) 
P=0.7402 
  
Double 
blinding 
1.18 
(0.84-1.66) 
P=0.3314 
1.01 
(0.76-1.33) 
P=0.9676 
   
Industry 
sponsor 
0.73 
(0.03-21.38) 
P=0.8564 
    
*Values in the brackets are 95% CIs. 
I used backwards selection to identify the best fitting parsimonious statistical 
multivariable model. The final model included country of origin and traditional 
Chinese treatments. Chinese trials were associated with an increased rate of 
positive results (OR=2.96, 95% CI 2.23 to 3.94; P<0.0001), Indian trials 
reported a similar rate of positive results to Western papers (OR 0.92, 95% CI 
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0.69 to 1.24, P=0.59).  Traditional Chinese treatments were associated with a 
higher rate of significant results (OR=1.81, 95% CI 1.21 to 2.7; P=0.004). 
 
 
Comparison among Pubmed papers 
Chinese trials were associated with an increased rate of positive results 
(OR=2.46, 95% CI 2.00 to 4.16; P<0.0001).  Traditional Chinese treatments 
were associated with a higher rate of significant results (OR=1.67, 95% CI 
1.05 to 3.04; P=0.004). 
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3.3 Discussion 
 
I compared Chinese and Indian RCTs with Western Trials from high quality journals 
because I considered that there were some important similarities between these two 
countries. Both are developing countries with very large populations and they are 
undergoing rapid socioeconomic transition. They are also recognised as potentially the 
two largest markets for pharmaceutical trials in the world, which can contribute 
important data on medical research and development.  
 
I found reports of Indian trials to be slightly better than Chinese papers on the trial 
reporting quality indicators: concealment, double-blind, intent-to-treat, reporting of 
primary outcomes, confidence intervals; and much better than Chinese papers on 
reporting patients’ ethical issues: informed consent and ethic committee approval.  
However Western trial reports scored considerably higher than both Indian and Chinese 
trial reports on all quality criteria. 
 
The rate of positive results was substantially different between Chinese and non-
Chinese reports of randomised trials. Reports of trials of Chinese Traditional Treatments 
included a higher proportion of positive outcomes than trials of conventional treatments. 
 
Although the pubmed papers are significant different from non-pubmed papers on many 
quality characteristics, however, on many quality characters, Chinese RCTs are still 
                                                                                                                              73
significant different to Western and Indian RCT papers. Therefore, the overall Chinese 
RCT report quality need to be improved.  
 
3.3.1 Strengths of this study 
To my knowledge, this study presents the first empirical comparison among Chinese, 
Indian and Western RCT publications.  I found poor reporting of all quality measures 
among Chinese and Indian trials, and strong evidence of bias in the reported results of 
Chinese trials.  
 
3.3.2 Methodological evaluation 
Essential details of trial design and quality need to be reported more clearly in Chinese 
and Indian RCT papers.  In my comparison, I found significant differences on those 
methodological details across countries. Schultz et al found inadequate reporting of 
concealment of allocation and the absence of double blinding were associated with 
exaggerated estimates of treatment effect in RCTs. 9 
 
The prior specification of a primary outcome measure is an important measure for the 
interpretation of a trial since this can avoid the statistical problems of multiplicity as each 
test conducted increases the probability of a false positive finding and thus increases 
the studywise type 1 error rate.  The failure to prespecify a primary outcome measure or 
α spending strategy may lead to inappropriate application of apparently positive results 
from trials when in fact chance alone may often provide an adequate explanation for the 
observed results.62 
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I appreciate that important methodological details may be omitted from published 
reports despite having been appropriately implemented within trials. For example, 
Soares found that authors of RCTs frequently used allocation concealment and blinding, 
but fail to report these methods12.  Journal editors, especially those who handle large 
number of trial reports from China and India, are important players in improving the 
quality of reports of trials through the active implementation of the CONSORT 
recommendations62.   
 
3.3.3 Ethic issues 
I observed significant shortcoming in the reporting of ethical issues in Chinese papers. 
Informed consent and ethic committee approval are widely accepted as fundamental 
requirements of conducting RCT in China but not all hospitals involving in trials have 
institutional ethical committees64 . 
 
3.3.4 Publication bias 
Chan et al found a substantial difference between RCT protocols and the final 
publication of their outcomes in many trials.26 Those outcomes with non-significant 
result were frequently omitted in the final report. In my study, I found Chinese papers 
reported fewer outcomes than Indian or Western trials, which could be the explanation 
for the high rate of positive results reported. Indeed, in some Chinese RCT papers I 
found the outcomes described in the methods and results sections did not match.  For 
example in a paper describing a trial of the effects of somatostatin on intestinal 
obstruction published in a Chinese medical journal, the operation rate was the only 
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outcome described in the methods section, but in the results section a further five 
outcomes were presented.65 In another trial report published in another medical journal 
which examined the effects of oxymatrine in the treatment of chronic hepatitis B, 22 
indicators were described as outcome measures in the methods section.  However, only 
6 outcomes were reported in results section, with 5 out of 6 of the reported outcomes 
indicating a significant result.66   
 
 
3.3.5 Limitations  
The sample of Indian trials may not have been representative; my search would not 
have located all published trials although it seems likely that I identified the highest 
status journals through my searches of Pubmed and ISI web of science.  But trials are 
published in many journals which are not indexed by Pubmed and ISI. Similarly, my 
search for Chinese trials through Medline and the Journal Series of the Chinese Medical 
Association may have included journals which are unrepresentative of all Chinese 
journals although because of my search strategy these may be considered the highest 
status journals publishing the most influential trial reports.  
 
Seventy-nine Indian papers were not available despite attempts to secure copies. This 
level of missing data could affect the final analysis and comparison results. However, it 
is reasonable to expect that the quality of papers published in those journals that do not 
produce electric versions or are not included in British inter library loan would be inferior 
than those that are more readily available. Therefore, if I was able to include papers 
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from the former journals, it is very likely that the average quality of Indian papers would 
come out worse. Further research is needed to verify this. 
I wished to investigate the effects of industry support in medical trials. However, I did 
not find enough information from Chinese and Indian trial reports to allow us to explore 
this issue properly.  
 
3.4 Conclusions 
 
My study focussed on the reporting of randomised trials, which may not exactly follow 
the conduct of trials.  I used the CONSORT recommendations for reporting of trials as a 
template for my evaluation.  This may mediate against trials from China and India as 
CONSORT may have less influence on trial reporting in those regions than in the West 
where it was developed and actively promoted by several major journals included in my 
work.  Thus the trials from China and India could be well conducted, but inadequately 
reported.  However the difference in positive results reported between Chinese trials 
and Western or Indian trials cannot plausibly be explained by the play of chance or the 
a priori identified confounding factors, and may be associated with the selective 
publication of outcome measures which showed statistically significant results. 
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Summary 
In this chapter, I compared Chinese and Indian RCTs with a gold standard sample of 
Western RCT publications. I found that Chinese RCTs are biased in many items, and on 
average Chinese RCTs present a higher proportion of positive results than Indian and 
Western RCTs. In addition, on many quality and ethical indicators, Chinese RCTs 
showed worst results, not individually, but systematically. What are the reasons why 
Chinese RCT publications are at such a low quality level? I will explore it though 
clinicians and patients’ knowledge and attitude in the next two chapters. 
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Chapter 4.  Barriers of Chinese clinicians to participation in 
randomized controlled trials 
 
Outline 
In this section I used questionnaires, focus group meeting and semi-structured 
interviews to describe Chinese clinicians’ Knowledge and attitude toward RCTs. They 
are the direct executors of randomized controlled trial, whose understanding and 
attitude will influence RCT and RCT publications’ quality. Results from quantitative 
research (questionnaires) and qualitative research (focus group meetings and personal 
interviews) are reported separately. 
 
In the previous chapter, I reviewed and evaluated Chinese RCT publications and found 
Chinese randomized controlled trial papers were not well reported, which is likely to be 
a reflection of the quality of trial conduct.  There is a substantial gap between leading 
Chinese and Western RCT publications in many issues, which may lead to Chinese 
RCT research being unconvincing among the international medical community. An RCT 
report with inadequate information and uncertain description risks being rejected by 
readers for quality reasons, and may not be included in meta-analysis.  Meta-analysis 
combines the results of several studies which address similar research hypothesis, 
providing a more powerful estimate of the true effect size than those derived in a single 
study.   
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Furthermore, from the previous systematic review, I discovered the substantial problem 
does not just exist in individual journals, but appears to affect the whole Chinese 
medical journal system, because the main source of evaluated papers is from the 
journal series of the Chinese medical association, and which is the well known medical 
journal series in Mainland China.  
 
The success of RCTs depends on the participation of clinicians. To achieve this, 
clinicians must agree to participate when invited, must recruite patients who are eligible 
(including offering participation to eligible patients) and must follow the trial protocol. 
Each of these stages represents a potential barrier to participation which varies from 
trial to trial. 
 
There are studies which have shown that trial participants’ failure to understand 
information about randomisation, even the provision of clear and readable trial 
information67. As a consequence, patients may create their own incorrect interpretations 
and consent that would influence their behaviours in RCTs and further the quality of 
RCTs. Clinicians’ understanding and attitude made effect on their behaviour of 
conducting RCTs68. The insufficient of RCT reporting on the main quality items are 
reflecting some practical problems, such as the ethical problems or patients’ allocations. 
Therefore, I would like to identify whether poor reporting reflects poor quality trials, or 
merely deficiencies in the medical paper writing. I would like to access the real RCTs 
conductors and participatants through focus group meetings and interviews, to assess 
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their understanding and attitude toward RCTs, and try to explain the reasons for poor 
quality RCT reporting,  
 
Research question 
What is the Chinese clinicians’ experience of conducting RCT? Do they have a correct 
understanding and positive attitude toward RCT? What are the barriers which may 
affect their conduct of RCTs in practice? 
 
I address several sub-questions: What is clinicians’ understanding and attitude towards 
randomized controlled trials? What are clinician’s clinical and research work profiles? 
Why they like or not like participating in RCT research? What are the barriers which 
block them from conducting better RCTs? Are there any characteristics from the 
Chinese medical system which may affect clinicians’ RCT work? 
 
I conducted a qualitative study to access Chinese clinicians, attempting to describe their 
working profile in practice and with patients, and analyze clinicians’ attitudes to the 
randomised controlled trial in depth.  
 
• The reason of using multiple research methods 
Questionnaires are perhaps one of the most popular data gathering tools, but there are 
a number of situations in which the interview is the most logical research technique. 
Both questionnaires and interviews have their advantages and disadvantages; 
questionnaires are low cost in terms of both time and money, the inflow of data is quick 
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and from many people, which is fit for detecting attitudes, motivation, opinions69.  Focus 
group could be employed to explore same information, but potential for explore answers 
in more depth; personal interviews provide more detailed and in-depth information70. 
The dialogue between interviewer and respondent allows for nuances to be captured 
and for questions to be clarified and adopted or improvised; in questionnaire surveys, 
nuances of the respondent’s voice cannot be heard and questions cannot be modified 
once printed. Therefore, in my research, I used questionnaire, focus group meeting and 
interviews to examine Chinese clinician’s attitude and knowledge of RCT research. With 
those high status ‘big man’ in the department, I conducted personal interview, which is 
more flexible and provide more in-depth information. 
 
 
4.1 Part One. Quantitative research: Physician Orientation Profile 
 
RCT research requires clinicians to take the role of being an investigator, a dilemma 
which cannot be avoided. We have to understand their attitude of being an investigator 
in a clinical setting and what the difficulties are that they met in practice, then I could 
prescribe effective solutions on policy making or improvement. 
 
The Randomized controlled trial was developed as a new research method by Western 
scientists and has been used widely in Western countries. There have been significant 
improvement in health care as a result of findings from clinical trials, but practical 
conduct problems are common, may cause delays, increased costs or lead to the failure 
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to complete trials71. Doctor-related factors have been cited as one of the primary 
reasons for poor conduct for clinical trial72. Barriers to trial participation for doctors71;73;74, 
as currently we known, include personal conflicts between the roles of clinician and 
scientist75; lack of rewards75, discomfort with random allocation of patients to 
treatment76; difficulty with ethics requirements and informed consent72; concerns about 
patients’ wellbeing and effects on the doctor-patient relationship76;77. However, when 
RCTs arrived in China, there have been some Chinese specialized barriers which 
hinder Chinese clinicians in conducting randomized controlled trial properly. Some of 
the reasons are from traditional Chinese culture; some are from the current Chinese 
medical system which I indentified from my quantitative and qualitative work of Chinese 
clinicians.  
 
The Physician Orientation Profile is a questionnaire which is based on the different roles 
of clinician and investigator, designed for clinicians to describe their attitude toward 
randomised controlled trials. It was used in main Western countries, such as US, UK, 
Canada, France, Australia and Poland.78;79 however, it had not yet been used with 
Chinese clinicians. A translated physician orientation profile was used with all 
participating clinicians. 
 
I translated Physician Orientation Profile into Chinese by myself. I also had a pilot study 
of Chinese version in July 2006, 28 Chinese clinicians involved. Their comments and 
suggestions were taken for the words correction. The final version of Physician 
Orientation Profile in Chinese was revised 4 times before it put in practice.  
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4.1.1 Method 
I would have liked to select research hospitals randomly among all the hospitals in the 
Guangzhou area, however, that was not practical because without the agreement from 
Guangzhou Public health bureau, selected hospitals would reject any access about their 
RCT conduct. I informed Guangzhou public health bureau of my research plan and 
discussed hospital involvement with them. I required participating hospitals to have 
substantial experience in conducting clinical trials. After initial meetings, 3 hospitals 
were nominated by Guangzhou Public health bureau which were First Municipal 
People’s hospital of Guangzhou, Guangzhou Red Cross hospital and Guangzhou Brain 
hospital. These 3 hospitals are all 3A+ hospitals with a clinical trial base and under the 
control of the Guangzhou public health bureau.  
 
First Municipal People’s hospital of Guangzhou and Guangzhou Red Cross hospital are 
both general hospitals, which Provide medical service to local communities and treat 
various types of diseases and injuries. Guangzhou Brain hospital is a special hospital 
for nervous system disease, which has conducted clinical trials for more than 10 years. 
These 3 hospitals were selected because they are typical hospitals with RCT 
experience, their clinician and patients are also typical. 
 
With the help of hospital research administrator, I sent questionnaires to all clinicians if 
he or she has the experience of participating RCT research within these 3 hospitals.  
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4.1.2 Analysis for Quantitative study 
 
Demographic variables were reported, practice variables and responds to individual 
questions were compared between Chinese and Western clinicians, using Z test for 
testing differences in proportions. Because the data from literature of Western 
clinicians79 are presented in percentage, so I presented corresponding percentages as 
well, and made comparison by giving Z and P-value. The SAS statistical program (SAS 
ver 9.2, Cary, NC) was used for data analysis. 
 
4.1.3 Result 
Questionnaire survey, performed between July 2007 and May 2008, in 247 Chinese 
clinicians from 3 hospitals of Guangzhou. With their hospital administrator’s help, I 
achieved a response rate of 95%, 234 of 247 clinician returned completed 
questionnaires. My study involved only those clinicians with experience of conducting 
randomized controlled trials, therefore not every clinician was eligible in a hospital. I 
tried to include every eligible clinician in the questionnaire study. As I mentioned before, 
this is the first study to investigate Chinese clinicians’ attitude of RCT, and the 
questionnaire was translated into Chinese language. Considering the substantial 
Chinese medical doctor population, this study only involved a small proportion of 
doctors within one city.  
 
4.1.3.1  Clinicians demographic characteristics 
Table 4.1 presents included Chinese clinicians’ demographic information.  
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Among 234 Chinese clinicians,158 (67%) were less than 40 years old, 108 (46%) were 
males. 124 (55%) had Bachelor degree, 94 (39%) had Master degree, 16 (6%) had PhD 
or MD degree. 74 (32%) were based ininternal medicine departments, 38 (17%) were in 
surgery, 50 (21%) were from mental health department (because the brain hospital was 
involved). 162 (70%) had no academic appointment, 44 (18%) were associate 
professors, 28 (12%) were professors. Only 24 (10%) clinicians reported that they 
spend more than 50% time on research, and only 34 (15%) clinicians had more than 3 
papers published every year. 
 
Table 4.1 Characteristics of included clinicians 
 Number  Percent 
Age   
30 years or less 74 31% 
31-40 84 36%  
41-50 56 24% 
51-60 18 8% 
More than 60 2 1% 
Sex   
Male 108 46% 
female 126 54% 
Education   
Below Bachelor Degree  0 0% 
Bachelor Degree 124 55% 
Master Degree 94 39% 
PhD or MD Degree 16 6% 
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Department    
Surgery 38 17% 
Internal medicine 74 32% 
Radiology  12 5% 
Paediatrics  12 5% 
gynaecology and obstetrics 18 7% 
dentistry 2 1% 
Mental health 50 21% 
others 28 12% 
Hospital setting   
1000 beds or fewer 158 68% 
More than 1000 beds 76 32% 
Income   
Primarily fee for service 22 9% 
Primarily salaried 212 91% 
Academic appointment   
No appointment 162 70% 
Associate professor  44 18% 
Professor  28 12% 
Activities    
50% research time or less 210 90% 
More than 50% research time 24 10% 
Authorship   
More than 3 articles/year  34 15% 
3  or few articles/ year 200 85% 
 
 
                                                                                                                              87
4.1.3.2 Chinese clinicians’ responses on Physician Orientation Profile  
The results from Chinese physician Orientation Profile were reported and compared 
with Western clinicians’ answers together, in order to show the difference between 
Chinese and Western clinicians.   
Because the data from literature of Western clinicians79 are presented in percentage, so 
I presented corresponding percentages as well, and made comparison by giving Z and 
P-value. 
 
Table 4.2. Physicians' Responses to the Binary-Option Questions of the Physician 
Orientation Profile 
 
 Chinese 
clinicians’’ 
responds  
N=234 
Western 
clinicians’ 
responds79 
N=250 
Chi-square P OR and 95% CI 
 
1. although many physicians are expected to perform both tasks, as a physician my primary allegiance is to 
a. future patient 
(society)   
28 27 
b. present patient 
(individual)                 
206 223 
0.07 0.79 1.12 (0.64-1.97) 
2.if I had to choose, I would say my primary task is: 
 
a. caring for 
individual patients      
187 225 
b. contributing to 
scientific knowledge  
47 25 
8.93 0.002 0.44 (0.26-0.75) 
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3.I would like to assess how successful I was as a physician by  
 
a. my research 
contribution                
16 36 
b. how I helped 
individual patients      
56 192 
c. both                        162 22 
188.4 
 
 
<0.001  
4. Although physicians strive to achieve an optimal balance, would you rather become somewhat too 
involved with your patient or somewhat to detached? 
 
a. too involved           186 212 
b. too detached          48 38 
1.99 0.158 0.69 (0.43-1.11) 
5. if a patient refuses to participate in the study, I : 
 
a. take him off the 
study                          
204 248 
b. refer him to 
another physician      
30 2 
26.37 <0.001 0.05 (0.01-0.23) 
6. I would rather be known for: 
 
a. my interpersonal 
skills with patients      
206 194 
b. my research 
accomplishments     
28 56 
8.46 
 
0.003 
 
2.12 (1.3-3.48) 
7. Overall I feel the quality of patients care 
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a. in creases in 
when a patient is in 
a clinical trial         
164 113 
b. decreases when 
a patient is in a 
clinical trial               
12 11 
c. does not change 
when a patient is in 
a clinical trial    
58 126 
34.07 
 
 
<0.001 
 
 
 
8. Randomised controlled trial restricts my ability to individualise patient care: 
 
a. true                        32 69 
b. make no different   202 181 
13.6 0.001 0.42 (0.26-0.66) 
9. I think the patient’s right to select treatment option is always more important than advancement of 
scientific knowledge 
 
a. yes                         88 175 
c. no                           146 75 
49.8 <0.001 1.9 (1.32-2.74) 
11. When there is controversy in the literature as to which treatment is best: 
 
a. I enter the patient 
in a clinical trial if 
one exists              
120 89 
b. I personally 
select a treatment 
for the patient            
114 161 
11.48 <0.001 1.9 (1.32-2.74) 
12.  When making critical and controversial decisions, I usually: 
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a. seek major input 
from my patients        
13 240 
b. do not  seek 
major input from my 
patient                       
221 10 
392 <0.001 0 (0-0.01) 
13. When published data and my clinical judgement conflict, I am more likely to rely on: 
 
a. my clinical 
experiences               
156 112 
b. published data       78 138 
22.5 <0.001 2.46 (1.7-3.56) 
14. When a protocol includes a treatment that is more aggressive than I would usually give to similar non-
trial patients: 
a. I am often 
reluctant to 
participate                  
151 128 
b. it makes no 
different                     
83 122 
8.26 0.04 1.73 (1.2-2.5) 
15. when a protocol includes a treatment that is less aggressive than I would usually give to similar non-trial 
patients: 
 
a. I am often 
reluctant to 
participate                  
151 100 
b. it makes no 
different                     
83 150 
28.16 <0.001 2.73 (1.89-3.94) 
16. I am reluctant to participate in a trial that may randomise the patient to a ‘no treatment’ group 
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a. yes                         149 70 
a. no                          85 180 
60.6 <0.001 4.51 (3.07-6.62) 
17. when I am personally uncertain as to which treatment is best, I am likely to: 
 
a. enter the patient 
in a randomised 
clinical trial if I am 
aware one exists    
175 138 
b. personal select a 
treatment                   
59 112 
19.45 <0.001 2.41 (1.64-3.54) 
18. when a potential eligible patient chooses not to enrol on a trial that I have suggested: 
 
a, I often feel 
disappointed              
121 72 
b, I seldom feel 
disappointed              
113 178 
25.5 <0.001 2.65 (1.82-3.85) 
20. ideally I would like to refer or enter the following proportion of my potential eligible patients into 
randomised controlled trial 
 
a. none                      14 8 
b. some                      145 135 
c. half                         14 13 
d. most                       55 63 
e . all                          6 31 
18.96 
 
 
 
 
<0.001 
 
 
 
 
 
21. the time I devote to publications, lectures and research commitments, compared to clinical work, is 
relatively: 
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a. totally clinical 
work                           
22 27 
b. mainly clinical 
work                           
155 153 
c. clinical and 
research equally        
47 45 
d. mainly research     10 19 
e. totally research      0 6 
8.84 
 
 
0.065 
 
 
 
 
22. Frequent publications are important to my career advancement: 
 
a. yes                         198 117 
b. no                          36 133 
74.4 <0.001 6.25 (4.05-9.64) 
23. I am more likely to attend a conference that focuses on  
 
a. Clinical issues        155 186 
b. research issues     79 64 
3.48 0.06 0.68 (0.46-1.00) 
24. in my hospital, doctors are given more reward for: 
 
a. clinical skills with 
patients                      
99 166 
b. contributing to 
scientific knowledge  
135 84 
27.35 <0.001 0.37 (0.26-0.54) 
25. If written informed consent was not required, I would approach more patients to enter clinical trails 
 
a. true                        113 24 
b. make no 121 226 
87.26 <0.001 8.79 (5.37-14.39) 
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difference                   
26. the need for detailed monitoring of my management of trial patients by trial staff deters me from 
participating in randomised controlled trial 
 
a. yes                         62 26 
b. no                          172 224 
19.98 <0.001 3.11 (1.89-5.12) 
27. The increased paper work involved in treating patients on trials deters me from participating in 
randomised controlled trials: 
 
a. yes                         77 94 
b. no                          157 156 
0.97 0.32 0.81 (0.56-1.18) 
28. the thought of having to spell out all the details of a trial to eligible patients discourages me from 
approaching them to participate 
 
a. true                        89 49 
b. false                       145 201 
19.26 <0.001 2.52 (1.67-3.79) 
29. a major reason for my participation in randomised controlled trials is that it financially benefits my 
institution or department 
 
a. agree                     67 26 
b. not agree               167 224 
24.72 <0.001 3.46 (2.11-5.67) 
30. Overall, involvement in randomised controlled trials 
 
a. enhances my 
reputation                  
101 111 
b. does not 
enhance my 
133 139 
0.03 0.85 0.95 (0.66-1.36) 
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reputation                  
31. if research activities were to enhance my income, I would enter more patients in randomised controlled 
trials 
 
a. agree                     101 63 
b. not agree               133 187 
16.61 <0.001 2.25 (1.53-3.31) 
32. when I participated in a randomised controlled trial, it is more likely that: 
 
a. I increase my 
patient population      
73 13 
b. I lose patients I 
might otherwise 
keep                           
14 15 
c. It makes no 
difference to my 
patient population      
147 222 
56.67 
<0.001 
 
 
 
 
 
33. my income rely on my research work 
 
a. yes                         20 26 
b. no                          214 224 
0.29 0.589 0.81 (0.44-1.49) 
35. in my hospital the pressure to participate in a randomised controlled trial is relatively 
a. low                         131 222 
b. no                          103 28 
64.29 <0.001 0.16 (0.1-0.26) 
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4.1.3.3 Responses to the five indices of doctors’ attitudes to involvement in RCTs 
• Primary allegiance79 
Chinese clinicians orientation, is towards the care of individual patients.(Q1, Q2)  
Chinese clinicians are more likely to take both clinical and research tasks at the same 
time, recognising that clinical practice is not their only requirement in the current 
medical community. A qualified modern clinician should connect clinical experience with 
medical research in their daily practice. (Q3) most clinicians thought that the overall 
quality of patient care increased.(Q7) Compared with Western clinicians, less Chinese 
clinicians thought that RCTs restricted their ability to deliver individual patient care.(Q8) 
 
• Decision making under conditions of uncertainty79 
 
When published data and clinical experiences conflicted, 67% of Chinese clinicians 
claimed they would rely on their clinical experience.  However, Chinese clinicians are 
less willing to refer a patient if they were personally uncertain about treatment than their 
Western colleagues (Q11), and less likely to seek a major input from their patients.(Q12) 
this is the significant difference between Chinese and Western clinicians, which maybe 
caused by Chinese traditional culture and the clinicians’ special status that I will discuss 
later. Chinese clinicians are more reluctant to put their patients in a trial involving a 
protocol that included a treatment that was more or less aggressive than their usual 
treatment.(Q14,Q15) 
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• Professional activities79 
Research plays a small role in most Chinese clinicians’ professional activities. Only 
2.6% Chinese clinicians would enter all of their potentially eligible patients into a 
research trial, whereas 23% would enter most patients. 
 
• Perceived rewards79 
Chinese clinicians perceived that they would gain more rewards for research 
contribution than clinical skills (Q24), and thought that trial participation made no 
difference to their patient population (Q32). The laborious recruitment process (Q25 
Q28), detailed monitoring of their management of patients (Q26), increased paperwork 
(Q27), and lack of financial reward (Q29, Q31) were significant deterrents for clinician 
participation in clinical trials. These results suggested that Chinese clinicians need  
more direct and indirect rewards from RCT research. Therefore, Chinese clinicians’ 
incentive system needs to be improved to enhance clinicians’ research interests. 
 
 
 
• Peer-group influence79 
Most Chinese clinicians perceived little pressure from their hospital to participate in trials 
(Q35). There is a strong culture for conducting research but not RCTs. 
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4.1.3.4 Some response with significant different results between Chinese and 
Western clinician 
Western clinicians believe patients’ right to select treatment option is prior to scientific 
knowledge advancement, but Chinese clinicians do not think so (Q9). Western clinicians 
seek major input from patients when making critical and controversial decision, but 
Chinese clinicians do not (Q12).   
 
When published data and clinicians’ personal judgment conflict, Western clinicians rely 
on published data, but Chinese clinicians prefer to rely on their personal experience 
(Q13).  
 
Frequent publications benefit to Chinese clinicians’ career much more than Western 
clinicians’. (Q22) Western clinician would get more reward for clinical skill with patients, 
but Chinese clinician would not. 
 
 
 
 
4.1.4 Discussion  
 
Conflict: Clinical doctor and researcher 
In the past, the traditional dichotomy of physician either as researcher or as clinician 
was useful in categorizing groups of doctors and predicting their behaviour. Clinician’s 
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reluctance to participate may be a significant behavioural consequence of the 
implication of randomized controlled trial79. The intensity of the physician’s response to 
the formal integration of conflicting roles suggests that physicians themselves have 
begun to question and ardently defend their definition of their core task.78  The 
Physician Orientation Profile is developed to gain a better understanding of clinicians 
who are expected to be both scientific investigator and primary caregiver. Therefore, 
two opposite groups were classified, one group is ‘therapist’ and the other is 
‘experimenter’. 
 
Experimenters declared a primary allegiance to generating scientific data, interpreted 
medical uncertainty as justification for randomized controlled trials, saw patient care as 
an outgrowth of research, altered their current practice on the basis of published data, 
emphasized the rational and technical dimensions of medicine and expressed a 
willingness to share data with colleagues. In contrast, therapists claimed that their 
primary allegiance was to the individual patient, believed that it is the physician’s 
obligation to reduce medical uncertainty by using personal clinical skills, viewed 
research as a possible outgrowth of patient care, gave priority to personal clinical 
experience rather than to published data, professed a loyalty to medical tradition, and 
declared a preference for individual patient care. The Declaration of Helsinki states that 
‘In medical research on human subjects, considerations related to the well-being of the 
human subject should take preference over the interests of science and society’, which 
is the basic requirement for all medical professionals.’ 
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Compared to Western clinicians, Chinese clinicians are significantly more willing to be 
seen as a medical doctor rather than a researcher. Chinese clinicians all have 
substantial experience of clinical practice; indeed every senior clinician could be called 
an expert in their own specialism. Compared with conducting research, clinical practice 
brings clinicians more praise from patients and greater financial returns, which are direct 
and visible benefits.  
 
Chinese clinicians are used to instructing patients, and making decision for patients, 
rather than follow their opinion. This is a substantial difference between Chinese and 
Western clinicians. Chinese clinicians consider themselves as leaders in the 
relationship with patients, which are different to Western medical relationship. In 
Western countries, clinician and patient are considered more equal in their relationship, 
and the Helsinki Declaration emphasizes that patients’ right of treatment selection is 
more important than scientific research.  However, it is certain that Chinese clinicians 
are not taking concern about these issues. 
 
 
 
4.2 Part Two. Qualitative research: focus group meetings and personal interviews 
 
Semi-structured interview and personal interview are also conducted to detect Chinese 
clinicians’ attitude toward RCTs.  Furthermore, I tried to find the in-depth reason through 
clinicians’ daily work.  
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4.2.1 Method 
 
A preliminary study, included focus group meeting, interviews and in-depth observation 
of 3 grand hospitals in Guangzhou. This is a study to detect clinicians’ knowledge and 
attitude. As I mentioned, there is no relative study conducted in China before, therefore 
my research is trying to collect frontline information as much as possible, both 
quantitative and qualitative research method are used to gather wide information.  
 
I had a formal meeting with research administrators of those hospitals and discussed 
with them the best way to access clinicians and patients. As a result I decided to post 
an advertisement on the hospital website; both clinician and patients were free to 
participate.  In case of a low response rate, each hospital research administrator 
nominated a group of clinicians to participate in my research, which was considered part 
of their routine training programme.  
 
 
 
4.2.1.1 Focus group meeting 
 
Focus groups are unstructured interviews with small groups of people who interact with 
each other80. They have the advantage of making use of group dynamics to stimulate 
discussion, gain insights and generate ideas in order to pursue a topic in greater depth. 
It is a useful technique for exploring cultural values and beliefs about health and disease.  
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An understanding of group processes and models of small group behaviour is helpful to 
offer insight into what can happen in focus groups and why. This can inform appropriate 
strategies to facilitate the group as it goes through different phases of the group process. 
 
I conducted 14 focus group meetings in these 3 hospitals, 5 in The No.1 hospital, 4 in 
the Red Cross hospital and 5 in the Guangzhou Brian hospital.  Following the principle 
of maximizing information, I repeated my focus group meeting among the eligible 
clinicians until I could not find any new information from the group meeting. The focus 
group meetings lasted 65-85 mins each, and were conducted in each hospitals’ meeting 
room.  
 
4.2.1.2 Personal interview  
 
Semi-structured interviews are used for getting more specific information, by asking 
open-ended questions80. The data obtained from qualitative interviews are used to 
increase our insight into social phenomena rather than assume representativeness. 
None the less, the issue of non-representativeness of people, and hence the limitations 
upon generalisability of results, is a criticism that is frequently encountered.  
 
30 senior clinicians were interviewed, 12 from No.1 hospital, 8 from Red Cross hospital, 
10 from Guangzhou Brain hospital. The interviews last 20 to 40 minutes each and take 
placed in senior clinicians’ offices.  All the interviewed clinicians are nominated by each 
hospital; all of them have the experience of conducting RCTs.  
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4.2.1.3 Focus group and personal interview questions 
1. What is a randomised controlled trial? 
2. What is your personal experience of randomised controlled trials? And what is 
your attitude towards conducting RCTs, positive or negative?  
3. What are the difficulties in conducting RCTs? 
4. Are there any benefits of conducting randomised controlled trials, personally or 
collectively? 
5. Based on your experiences, what do you think is the job of ethics committees in 
conducting randomised controlled trials? And what is the reality? 
6. What is your suggestion of improving RCTs conducted in China? 
 
 
4.2.2 Procedure  
Every Wednesday and Thursday afternoon were the regular training time of clinicians in 
these hospitals. That is the time for health professionals to learn updated information 
about their medical area. Although 100% of the participants were nominated by the 
hospital they were interested in the study when they heard about the research questions, 
because this study is the first time experienced clinicians had come together to discuss 
RCT problems, especially some of the more practical problems. The focus group 
meetings provided professional medical doctors a good opportunity to discuss practical 
problems with their colleagues in the same medical area or in different medical areas. 
 
                                                                                                                              103
The focus group consisted of 8 participants each time, that all had experience of 
conducting RCTs. I, as the facilitator, introduced myself and gave a brief background to 
my research at the beginning, then asked them to introduce themselves one by one.  
This was followed by a discussion using open ended questions and a semi-structured 
questionnaire. 
 
At the beginning of the focus group, I introduced myself and welcomed all participators 
warmly, in order to put them at their ease by friendly conversation. I introduced some 
basic information about randomised controlled trials and my research background with 
the following words: Randomised controlled trials are known as the gold standard of 
medical research, every new drug and treatment needs to establish certain information 
from a RCT before it can be used widely. However, in recent years researchers found 
there are many problems in RCT conduct, which would relate to RCT participatants, 
including clinicians and patients. We would like to hear from you, as an experienced 
clinicians about the problems you encounter as a researcher / participant in RCTs. We 
hope you could share your experiences with your colleagues and us, in order to make 
RCT conducted in China more effective and efficient. 
 
Following this I asked the group to introduce themselves, with the aim of them getting to 
know each other and to build up a degree of familiarity. However, I found that 
participants did not like to do introduce themselves, because they felt they already knew 
each other within the group and I was the only one they needed to be introduced to. 
Since they were all the clinicians of the same hospitals, it is understandable that they 
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already knew each other. Therefore, if they did not want to introduce themselves to 
each other then I would omit this part of the focus group.   
 
It is impossible to gather all senior doctors together to conduct a focus group meeting, 
therefore I arranged a personal interview for those senior doctors unable to attend the 
focus group. The senior doctors were nominated by the hospital study administrator.  I 
was introduced to the senior doctors by the hospital study administrator and made the 
appointments myself. The questions in the personal interviews were similar to the 
questions asked at the focus group meetings. Questionnaires were left with senior 
doctors if they did not feel able to complete them immediately. Personal interviews 
lasted 10 to 15 minutes each. I introduced the same information as when conducting the 
focus group meeting.  
 
 
 
4.2.3 Analysis  
I am using ‘thematic content analysis’, which is the most basic type of qualitative 
analysis. It is to an analysis of the content of the data to categorize recurrent or 
common ‘themes’. 
Using the transcript from all my interview recordings, I categorized interviewees’ 
accounts in ways that can be summarized. It is essentially a comparative process, by 
which the various accounts gathered are compared with each other to classify those 
‘themes’ which recur.  
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Analysis must be purpose driven81 and the style of analysis must be directed towards 
answering the research questions. My analysis, therefore, was based on selective 
coding that focused on normative claims that were relevant to the research questions. 
Coding was carried out as a method of organizing and managing meaningful segments 
of data82, and was the first stage in the formal analytic process. Codes were attached to 
the data, and multiple codes were often attached to same segment. Multiple coding is 
warranted when a coded segment is both descriptively and inferentially meaningful70, 
and the data was generally rich in both kinds of meaning. 
 
In order to keep the segments in context, I refrained from coding small segments of 
speech and coded larger sections, often including the parts of discussion prior to and 
immediately after the segment of interest. This made coded segments very substantial 
but ensured that the context was not lost upon retrieval.  
 
Coding as the first stage in formal analysis, was selective and focused on the meaning 
of the data rather than on the word used70 As such, the coding itself was an interpretive 
process, in which meaning was elucidated through my own understanding of the 
significance of the context in which the words were uttered69.  
 
Coding was performed in two streams. The first stream was ‘free coding’, in which the 
data was taken at face value and codes were attached without particular reference to 
previous data sets.  This simply means that the ‘primary coding’ was conducted in an 
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unstructured way, focusing on the data set and generating codes solely in reference to 
that. The second stream was performed based on those free codes and aimed at 
standardising the codes so that the groups could be compared and analysed using the 
same conceptual framework. No attempt was made to limit the number of codes used in 
the first stream only those codes that had been replicated or could be replaced by an 
existing code were removed. 
 
This method was chosen because the very large data set meant that too rigid a coding 
framework from the start would inhibit full analysis, but not enough of a framework 
would make the data uncontrollable. The two stream system compromise was labour 
intensive, but was advantageous insofar as it allowed sufficient conceptual freedom to 
ensure the analysis did not become conceptually bound by what had gone before, but it 
also provided enough of a framework to ensure that coding was performed consistently. 
The two stream coding also helped to reduce the possibility of bias, and helped me to 
maintain a sense of objectivity during coding. Using standard codes from the start would 
have increased the temptation to use existing codes that did not quite fit, rather than 
produce new codes and increase the workload. By giving free reign to start with and the 
standardizing later, I allowed the creation of new codes as and when necessary. I found 
multiple codes that were unnecessary, which I subsequently removed and re-coded 
using the previous standard.  
 
Excel was employed as a tool to help manage and organize data under categories, 
facilitating easy retrieval of coded segment and providing efficient way to store the data. 
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4.2.4 Results 
The focus group meeting and personal interview were taken placed from July 2007 to 
May 2008.I divided clinicians into two groups: a senior clinician group and a junior 
clinician group, because I found their working characteristics varied from my interviews. 
Senior doctors were defined as an associated chief and chief doctor; junior clinicians 
were defined as clinicians in charge, or resident clinician. Although these two groups 
work together in the same department, their duties derived from their positions are 
different. In the RCT context, senior clinicians are in charge of administrative work, but 
junior clinicians are the people who execute the trial in practice. I tried to describe their 
different working characteristics in detail, which would help understand clinician’s 
behaviours, and found different way to investigate their RCT work. 30 senior doctors 
and 112 junior doctors participated in my interviews. Each hospital has conducted a 
number of randomised controlled trials in different departments including digestive, 
respiratory, urinary, incretion and surgery. 
 
In my study junior clinicians are defined as clinicians in charge and also resident 
clinicians. These two different groups of clinicians were grouped together because of 
their common characteristics and similar working status in randomized controlled trials. 
 
 
• Age and sex 
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Most senior doctors interviewed already had PhD or MD degrees (25 of 30); the 
remaining 5 have a Masters degree and are currently completing their PhD studies.  
Their age ranges from 39-65, with a mean age of 52, and median age of 49, 24 of the 
interviewees were male, whilst 6 were female. 
 
In comparison to senior doctors, junior doctors are of course younger; in my study I 
interviewed 112 junior doctors, whose age ranged from 26 to 36, (mean is 29.3, median 
is 28).  Their clinical work experience ranges from 1 to 12 years. Male clinicians (64) 
were more common than female clinicians (48).  
 
• Knowledge and experience of clinical practice 
Senior doctors interviewed all have at least 20 years of clinical experience.   The 
number of patients’ seen is a reflection of this experience. I asked senior clinicians how 
many patients they had seen and most of them said ‘that is hard to say, it is certainly a 
big number.’  On the other hand, senior doctor are all clinical experts, they are often 
invited to consult for difficult cases among different hospitals. As senior doctors they 
have a low complaint rate from patients and the expectation is that they are highly 
skilled in clinical treatments. 
 
An academic degree is increasingly important to Chinese clinicians, especially for 
professional clinical doctors. Ten years ago, a medical school graduate could start his 
clinical work with a bachelor degree, however, now it would be difficult to find a medical 
job in a hospital with only a bachelor degree. Increasingly hospitals require their medical 
                                                                                                                              109
employees to have good bachelor degrees upon entrance, and then encourage junior 
clinicians to study part-time for higher degrees. Therefore, from my research, I found 
junior doctors in these 3 hospitals all either have, or are aiming to obtain, master 
degrees on clinical science.  
 
• Experience of conducting randomized controlled trial 
The senior doctors interviewed all have experience of being the director or coordinator 
of randomized controlled trials. From discussions in the interviews they are 
knowledgeable about conducting randomized controlled trials, especially on a practical 
level. They were aware of good practice standards of RCTs; what the barriers are, and 
the best ways to solve them.  
 
Senior doctors have much experience of managing RCTs, but junior clinicians have 
more experience on recruiting participatants. They are participating in RCTs as frontline 
researchers.  Their works also includes talking to patients, obtaining informed consent 
and collecting data.  However, from my research, I found that they often had not had the 
opportunity to look though the whole study completely. Therefore, few of them have a 
comprehensive understanding about randomized controlled trials.  
 
When asked the question ‘have you participated in randomized controlled trials as a 
researcher?’ all junior doctors responded ‘yes’. They described their jobs in randomized 
controlled trials, for example ‘when the chief doctor (senior doctor) of my department 
agreed to do a randomized controlled trial, a project manager would come to our 
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department and have an introductory meeting. They explained their research proposal 
to make us understand what kind of patients they are looking for’ (J17).  
 
‘My job is to find the right patients for them to conduct research.’(J5) ‘I talk to patients, 
introduce the research project, and seek their agreement to join the research.’(J12) 
‘When they have agreed to participate, I would let them sign their name in 
documents.’(J34) ‘Some specific body-examination would be required for a randomized 
controlled trial; I record the result.’(J56) ‘ If the participating patients are not feeling well 
during the research processing, I have to take care of them. Most participating patients 
are in-patients; I have to watch them all the time. Anyway, any in-patients would be 
taken care of by our clinicians.’ (J58) ‘There is some monitoring from the 
pharmaceutical company; they would come to the hospital to view patients and data 
quality. At last I hand in all data to him.’ (J24) 
 
When I asked, ‘after handing in all data to the monitor, what you will do next?’  Junior 
Clinicians answered for example, ‘usually, my job is then finished. Later they will inform 
us about the trial result.’ (J1) Most of the junior doctor responses were similar in this 
regard; they only participated in patient recruitment and not the other stages of 
randomized controlled trials. Junior clinicians’ understanding of clinical trials is mostly 
around patient recruitment. However, one junior clinician told me he was willing to do 
some data analysis for the trial, but due to some contract regulation, he was not allowed. 
Some junior doctors need to have publications for their academic degree or working 
promotion and they would like to have some publications from their daily work; however 
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this is hard to put into reality. From my interviews, I was told that some randomized 
controlled trial projects had already decided who and how to deal with the data analysis 
before hand; so after the project started, they would not allow others to join the analysis 
group.  
 
• Busy working hours but limited research time 
Senior doctors state that they are very busy.  Their working hours are from 8am to 5pm, 
including a two hour lunch break. Usually they arrive in the hospital before 8am, and 
see all patients on the ward, listen to junior doctor’s updates of each patient’s disease 
information, and prescribe treatment. Each senior doctor would take responsibility for a 
small group of patients; usually between 10 and 20. Therefore, from my personal 
observation, senior doctors knew each of his/her patients quite well.  
 
Senior doctors are required to work in clinic at least three day per week. Their clinic 
working time is fully booked. They are required to see a certain number of patients, 
usually 20, in the morning section or in the afternoon section. On the other hand, there 
is often a waiting list of patients wishing to make appointments with senior doctors, and 
there are always some patients waiting outside of senior clinicians’ offices hoping to see 
the clinician as soon as possible. Therefore, senior clinicians’ workload can be 
substantial, the bigger hospital the bigger the workload. 
 
Although many senior doctors work more than 8 hours per day, they find only limited 
time in which to do research. This is especially true for famous surgeons, who spend 
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almost all of their working time on clinical practice. On the other hand, their clinical 
works were praised by patients, as from an individual patient’s point of view; they are 
seeking the best doctor in clinical practice, not in medical research. It is maybe 
therefore quite understandable for clinicians to have more interest in clinical activities 
and not research.  
 
On the other hand, hospital regulations state that clinicians are required to work in clinic 
or take time with patients; and there is not any requirement for clinicians to do research.  
Therefore, overall clinicians’ patient requirements mean that they have little time for 
research. To participate in an RCT, they could recruit patients from their clinical work, 
however other tasks that form part of a randomised controlled trial, are time consuming 
and difficult to create time for. 
 
Junior clinicians often work long and inflexible hours, with shifts at unsociable times, 
and may earn less than other professionals whose education is of comparable length. 
They have at least 2 overnight shifts every week, and their working hours totals over 55 
per week. In some departments a shortage of formal employed staff means they may 
work even longer hours.  When they are on duty, they are in charge of all in-patients; 
any emergency incident would be treated immediately.  
 
 However, not all duty time is spent treating patients,  Some of the time will be spent 
recording disease information, making diagnoses, dealing with prescriptions and 
updating their in-patients’ medical records. Junior doctors spend most of their time on 
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seeing patients and writing medical records. In my study I found 62% of junior doctors 
are aiming to obtain higher academic degrees by attending part-time courses. The 
higher degree is required in order to achieve promotion, and Publication is required to 
obtain the degree. It is stated clearly by the medical school that postgraduate students 
need to publish a certain number of papers in Chinese core medical journals in order to 
receive their Masters degree and varied but more strict publication requirement for PhD 
or MD degrees. The requirement of quantity and quality of publication varied in different 
medical schools.   
 
• Relationship with local medical community 
Chinese senior doctors all develop and maintain good relationships with the local 
medical community. There are a number of medical associations at national and 
provincial level.  In addition, they are all alumni of medical schools. In each large and 
middle-sized city in China, there are at least 2 medical schools, and the medical schools 
are attached to local hospitals.  When medical school students graduate, they tend to 
prefer to work in their local hospitals with only a small amount of graduates migrating to 
other hospitals. Thus most doctors within a hospital graduated from the same medical 
school and therefore they tend to have similar backgrounds.  
 
In China, each specific disease area has its own association at a national, provincial 
and municipal level.  Senior doctors all hold important positions in the medical 
associations. There are many opportunities for senior doctors to study, such as 
conferences or short training courses.  
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• Relationship with local community 
In order to keep good relationships with the local community, hospitals frequently 
introduce free consultations or treatment to the public. Hospitals, as a professional 
medical unit, have an important responsibility for the health promotion and education of 
their local communities. Senior doctors are always the main organizers of these 
activities. The hospitals require each department to do some consulting or health 
promotion activities, and the senior doctor’s name is utilized as the best advertisement. 
  
On the other hand, the good relationship is from their occupational position, not from 
their personal characteristics. As previously mentioned, doctors were considered as 
‘representative of God’ or ‘God’ in ancient China39. During the last 100 years, China has 
suffered war, poverty and disease and an extreme shortage of professional medical 
doctors.  As a result, healers and ‘magic’ came back to Chinese rural areas. When the 
Peoples’ Republic of China was founded, the government introduced scientific 
treatment to citizens, and banned healers from treating patients. Medical doctors were 
described as ‘representatives of science’ and replaced the magic healers. Therefore, 
medical doctor as an occupation was linked with terms such as ‘professional’ 
‘advanced’ and ‘authority’. 
 
Junior clinicians concentrate on their personal routine works, however, in addition, they 
are keen to enhance their personal reputation in the medical and local community as 
well.  A high quality of clinical service and an abundance of medical publications are the 
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two substantial elements contributing to a clinicians’ reputation.  Junior clinicians are 
taught this; therefore they work hard in their clinical practice and seek any possible 
opportunity to participate in medical research. The good reputation of a clinician would 
encourage patients to choose them with more confidence, which would bring more 
direct and indirect benefits to clinicians in terms of honours and incomes.  
 
In my research, junior doctors recognized the need to enhance their personal 
reputations in order to achieve their ambitions and career progression, for example ‘I 
am only a tiny guy in my department. My department director, Dr XX, he is the expert in 
this area. He is famous, not only in medical area, but also in the local community. I need 
to work about another 20 years, I hope I could reach his level.(J23)’ I recognized that 
they respect the senior doctors in their department and wish to emulate their careers by 
becoming famous clinicians themselves. 
 
 
 
•  Are Doctors Satisfied with their Income? 
 
In all RCT research, the participated investigators will get financial award for their work, 
those incomes is not included in their salary. The amount of this income is depending 
on their workload, more work means more income. 
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In my research, I found that Chinese senior doctors are generally satisfied with their 
income. Their incomes included basic salary from the hospital, research work rewards 
and grey incomes. Grey incomes include ‘red envelopes’ from patients and prescription 
bonuses from pharmaceutical companies.  (The original meaning of Red envelop39 is 
the gift money which was given in holiday or special occasions, which is also used to 
deliver bribes.)  Senior doctors have the power to allow or forbid junior doctors to 
prescribe a certain drug. There is no specific regulation to restrict clinicians’ prescription 
bonuses which is still a substantial part of clinician’s income.  
 
For many physicians, in particular those at big hospitals, specialty hospitals or hospitals 
with large reputations, physician incomes can be larger than regular hospitals. 
Physicians, and in particular, surgeons, can augment their hospital salaries by operating 
surgeries at hospitals other than the one in which they are employed. Many physicians 
also receive commissions from prescribing prescription drugs and get “red envelopes” 
from patients or from sales representatives of drug companies. However, a new 
regulation issued by the Health Ministry removes physicians from the practice of 
medicine if they are found to have taken "red envelopes" from patients, and a hotline 
has been set up to monitor physicians. 
 
Another big part of their income is the bonus from prescriptions. As we know, the 
competition between pharmaceutical companies is fierce, especially in China. The 
Chinese medical market is large and there are a number of medicines with similar 
curative effects but that are produced by different pharmaceutical companies. 
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Pharmaceutical Sales Representatives attempt to access clinicians, especially the 
senior doctors, in order to make them understand their products and prescribe these to 
patients rather than other opponent pharmaceutical companies’ drugs. Financial 
encouragement is still a substantial way to stimulate sales volume. There is no relative 
regulation from hospital to forbid these activities and more and more pharmaceutical 
companies accepted this ‘sub-principle’ in medicine sales, then clinicians would like to 
take this bonus from their daily work. Furthermore, as the senior member, those doctors 
would be more concerned with pharmaceutical companies than junior doctors, more 
advanced gifts may additionally be sent to senior doctors, such as free shopping 
vouchers or free family holidays. 
 
When I asked junior clinicians about their incomes, most of them responded that they 
were ‘not satisfied’ ‘I am poor in this city’. Like other clinicians, their incomes include a 
basic salary, department bonus and prescription bonuses. The prescription bonus is a 
substantial part of a clinician’s financial income.   There is some research that suggests 
that prescription bonuses take the leading part of clinicians income83. In addition, 
Guangzhou is one of the most developed cities, both the average income level and 
consumption level are higher than in other Chinese cities. Usually, junior clinician’s 
salary level in comparison to their years of education is not considered satisfactory.  
Junior clinicians have more financial pressure than senior doctors, because junior 
clinicians are younger and have the pressure of having their own family, getting married 
and buying a house. Therefore, junior doctors are motivated to work hard in the hope of 
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gaining a promotion, because a higher position in the hospital would bring them more 
financial return. 
 
 
 
• Ethical approval  
Senior clinicians have a good understanding about getting ethical approval before 
starting the research. Some of the senior doctors are members of ethics committees of 
the hospital, local medical association or provincial ethics committee. There are many 
different kinds of people involved in ethics committees, for example, lawyers, nurses, 
lay people and experts in certain disease areas. Senior doctors joined ethic committees 
as medical experts, and their opinions carry great weight in the committee. 
 
‘When we received a research proposal, each of our committee members would judge 
whether to take it in on from our personal professional view. The research manager 
would come to give a presentation, and then we discuss the project within committee, 
and then all of our members vote to have the final decision.’ ‘Normally, when the 
research manager come to us and give the presentation, I already have an idea about 
whether to give approval or not. I am a senior person in this area. I think I understand 
about all the disease principles in this area. I know what kind of treatment would make 
patients feel better, and some of the medicines side effects; I know how bad it is. If I feel 
the research design is not good enough, I mean, if there is some good treatment, but 
they choose placebo as a comparison group, I would certainly say no to them, whatever 
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they pay us for doing research.’ ‘There are many researchers, especially those multi-
centre, large, randomised controlled trials, which got ethical approval from the 
committee of Beijing or from provincial level ethic committee. When we see the approval 
from upper level, we have to give approval as well.’ 
 
Ethics committees are not a new concept to Chinese clinicians.  Although Chinese 
medical professionals have conducted their research since the Peoples’ Republic of 
China was founded, no research work is conducted in mainland china without getting 
ethical approval before hand. With the development of medical ethics, Chinese medical 
professionals have recognized that there should be ethics committees in our medical 
systems. Therefore, in just a few years, almost every grade 3 hospital, medical schools 
and medical research institution has their own ethics committees.  However, there are 
still some problems on ethic committee’s working mechanisms such as the lack of a 
medical ethicist and working experiences. 
 
 
 
•  Informed consent  
Informed consent is the way we introduce the research to patients and get their 
agreement to participate in the randomised controlled trial. Senior doctors do not usually 
handle informed consent. They usually send informed consent to junior doctors, and 
then await their reply with the patients’ signature. Without the patient’s signature the 
senior doctors would not allow those patients to be involved in the randomised 
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controlled trial. ‘Without patients signature we could not put the patient into our clinical 
trial, which is the routine procedure of clinical trial. We have to comply with the 
regulation.’  
 
From senior clinicians view, they think it is not difficult to get informed consent from 
participators. ‘Usually, if we clinicians asked patients to join the research, most of them 
would agree to participate.’ ‘I don’t think getting patients signature is difficult, at least 
from my experience, our department always could have enough patient participants for 
research.’ 
 
Junior doctors describe the ethical issues of randomized controlled trials as: 
‘Our hospital has an ethics committee, without their agreement, research can’t start, not 
only randomized controlled trial, but also other types of research.’(J34) ‘ I know ethic 
committee’s agreement is quite important for trial start, without it, it is illegal.’ (J35)  
‘When our department accepted to do this research, I think this research had already 
passed ethics committee approval.’(J43) ‘We are in the executive level, about ethics 
issues, which is conducted by senior doctors and administrative staffs in our hospital.’ 
(J45) 
  
From my research it appears that junior clinicians in Chinese hospitals know it is 
necessary to obtain ethical approval for research (including randomized controlled trials), 
which is the preliminary procedure of doing research. Although junior clinicians have no 
idea about how ethics groups produce approval for the research. 
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• Attitude to participate in research 
From the personal interviews which I undertook, I found that Chinese senior doctors are 
willing to participate in research, regardless of the research topic. Senior clinicians are 
also the senior staff at medical school so to achieve and maintain an advanced 
academic title not only requires clinical skill and diverse experiences, but also the ability 
to conduct research.  
 
They prefer to lead research rather than participate in research, which requires financial 
support from national, provincial, municipal or school level. However, the competition for 
rewards is fierce; therefore, most of them are involved in joint-leadership of many 
research projects.  
 
A Chinese clinician is very busy in his clinical work everyday as they manage a large 
patient population. However, if a clinician would like to do some medical research, it is 
not easy to find an opportunity; they are often passive in medical research. Usually 
when a research project is accepted by senior doctors in the department, then several 
junior clinicians would be required for the project team. Then junior doctors would be 
invited to study. In most of these studies, junior clinicians will not get a publication at the 
end of it, thus junior clinicians are not enthusiastic of participating in the study and it is 
just treated as an order from senior clinicians. 
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Junior clinicians cannot connect medical research they have participated in to their 
promotion achievements. From my study, all junior clinicians told me that in big 
research studies (such as randomised controlled trials), it is unusual for them to achieve 
authorship of a publication. Due to their hospital promotion requirement, these non 
authored publications of research in which they played a part do not contribute to their 
promotion aspirations.  
 
Many junior clinicians feel that this process is unfair. They all carried out trivial but 
important jobs with patients but the rewards of this were limited.  For example, ‘I spend 
much time on patients for those researchers, but there is no record of my hard work, 
only my supervisor knows how hard I worked.’ Therefore, if their work could be related 
to their promotion, that would help to increase their enthusiasm for medical research.  
 
 
4.2.5 Clinicians’ Knowledge of randomized controlled trial 
 
• Definition of randomized controlled trial 
The definition of randomized controlled trial is as follows, 
‘Randomized controlled trial’ is an experiment for new drug and new treatment, through the 
comparison with placebo or other treatment, in order to make sure what is the effective and 
efficiency of the new drug/treatment.’ 
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Most of my interviewees gave similar responses; therefore I believe they have good 
understanding about the definition of an RCT. 
 
‘It is a scientific research method for new drug. Before the drug was accepted broadly, 
RCT is the necessary test for drugs. There are 4 stages of clinical trial, stage one is 
toxicity and pharmacology trials, which are concerned with drug safety. Stage two trials 
are conducted on patients only, without a control group. On Stage three, there are 
randomized controlled trials, with a control group and based on a large population; In 
China, stage two and stage three are usually combined, so there are no real stage two 
trials. Stage four is the post-market research about the drug.’ (S21)*   
 
‘A group of patients were randomized and allocated to two or more research groups, 
with active drug or placebo, and do statistical comparison between groups about 
patients’ disease progress, then draw a conclusion about whether the drug is efficient or 
not.’(S16) 
 
Most of my interviewers could give a similar answer. I believe they had good 
understanding about the definition of RCTs. 
 
                                                 
* * This citation is from my interview record. S is abbreviative word  of Senior, the number followed is my interview 
order. J is  abbreviative word of Junior, P is abbreviative word of Patient. 
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When I carried out the focus group meeting in the Red Cross hospital, I asked about the 
definition of a randomized controlled trial.  Responses (below) suggested they had 
received training about RCTs and understood it’s purpose and usefulness.   
 
‘Clinical trial is defined as planned experiments involving patients, the purpose of which 
is to determine the most appropriate form of treatment for future patients, this includes 4 
phases. Randomised controlled trial is the phase 3 trials, which involve a comparison 
group, receiving the new treatment with a control group, usually receiving a standard 
treatment or a placebo. This is the most rigorous and extensive type of scientific clinical 
investigation of a new treatment, which is considered the ‘gold standard’ in new medical 
research.’ they told me that their department as clinical trial unit passed quality 
inspection just a few days ago, which was conducted by the relevant medical and health 
administrations. As a clinical trial base, it should be inspected at a municipal, provincial 
and national level frequently. As members of the clinical trial base, they are required to 
have adequate knowledge of randomized controlled trial. Therefore, they had collective 
training about the randomized controlled trial on its definition and methodology. 
• Randomization and the reason for using randomization 
 
Senior doctors all had good knowledge of randomization; they described randomization 
as ‘a scientific method, statistical method. A statistician created a number sheet, which 
was created based on a certain statistical method’ (S12) 
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 ‘Usually we got a computerized random number list, which was used to allocate RCT 
participants.’(S21) 
 
An important issue in design is to ensure that the allocation of the treatment to patients 
is independent of the characteristics of the patients, so that when we come to compare 
groups, they will differ only in the treatment given. Randomization is the accepted 
method of eliminating allocation bias in clinical trials. 
 
I believe that they are aware that randomization is important in patients’ allocation; 
however, few of them could clearly state the reason for this. Clinicians’ understandings 
of why randomization is used are poor. 
‘It was used for scientific reason;’ (S8) 
 
‘It was used to allocate participators in different treatment group.’ (S9) 
 
‘I was told have to do this in the RCT study; because it is a multi-centre study, we have 
to follow the same regulation as other centres…. Statisticians know the reason why we 
should do it’ (S17) 
 
Junior clinicians stated ‘It is a word from statistics, which is to allocate patients into two 
or more trial arms.’ ‘It is a statistical method to put patients into two groups without 
particular order’ ‘statisticians do that, and that will help on their final data analysis.’ 
‘Randomization is the way to avoid bias in experiment, which is a scientific method to 
allocate patients.’ 
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They describe the meaning of using randomization is ‘to allocate patients, make two 
groups with similar patients’ ‘ make the trial group and placebo group the ‘same’ at the 
beginning.’(Of course they are not really same, but differ only on the basis of the play of 
chance.) ‘Usually they have a random number sheet, but as a researcher, I only have a 
patient’s number and their medicine code. I know randomization is quite important to 
this research.’ 
 
• Blinding 
 
Senior clinicians appear to understand blinding quite well. ‘Blinding is quite important to 
randomized controlled trials, without blinding, the accuracy of randomized controlled 
trial would be low.’ ‘Blinding is not a difficult definition in randomized controlled trials, as 
a researcher we should put our personal preference aside from the real data, therefore I 
think blinding is a good way to help us record just true data.’  
 
Senior clinicians know the principle of blinding, so they preferred to be blinded. I asked 
them whether they did guess the patients’ allocation, they told me: ‘yes, personally I did. 
But I haven’t communicated patients’ allocation with my colleague or patients.’ ‘I have 
some suspicion, but I think it is useless to talk about patients’ allocation. We were 
blinded. As a scientific worker, I should comply with research rules.’  
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Junior clinicians had a good understanding of blinding and its definition. ‘Most research 
is double blind or single blind. Blinding is a method by which the participants, clinicians 
or patients are unaware of which treatment group they are in.’(J40) ‘ in some of the trials, 
we clinicians don’t know which group these patients are in, that is the double blind trial, 
but in some trials, we clinicians could not be blinded, because of its specified treatment, 
that is a single blind trial’.(J41) 
 
 ‘Blinding is the method which keeps clinicians and patients’ personal psychological 
effects separate from the treatment result. Psychological effect would certainly influence 
treatment result.’(J45) ‘I think blinding is quite important in randomised controlled trials, 
which bring placebos into play.’(J47) 
 
All junior clinicians I spoke to had good understanding about the meaning of using 
blinding. At least they had understood the blinding principle, but found it hard to execute 
in practice. 
 
I observed clinicians in their work; I found most clinicians can’t blind their patients during 
the whole RCT process. When conducting a double blind trial, clinicians are often quite 
curious to know which patients are taking the real medicine. Also, some participating 
patients keep asking clinicians whether they are in a new drug group; if they found out 
that they were not they would withdraw from the trial.  Some clinicians felt under 
pressure to guess whether the patient was in the drug group. Therefore, it appears that 
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blinding is easy to understand in methodology, but hard for Chinese clinicians to 
operate in practice. 
 
• Where did senior doctors learn about randomized controlled trials? 
 
Senior doctors are all over 40 years old. In my interviews, I found that almost every 
senior clinician had been trained, (within the last 6 months to 2 years). Although senior 
doctors had a good understanding about randomized controlled trial, that knowledge is 
more from their practical work but less from their education. I was told that 
  
‘When I was in medical school, I studied clinical knowledge and practice my work in 
hospital. I had no idea about what is randomized controlled trial.’ (S1) 
‘In recent year, there was more and more RCT research conducted in hospital, but just 
a few years ago, I have no idea about what it is.’(S2)  
 
‘I learned RCT in my work;’ (S3)  
 
‘When a new RCT project start, people from pharmaceutical company or from leading 
institution will come to our hospital; and they usually give a speech to explain their 
research method, where I learned many new skills from.’ (S4) 
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 ‘Our hospital have the qualification of play clinical trial, which is in order to get this 
qualification; we have to be trained and pass some exam. I learned a lot from these 
training.’ (S6) 
 
‘Well, I can’t remember whether I was trained clinical trial in school, you know, I am a 
clinical student, not good at statistics, which I only learned a little. Anyway that is not my 
main course.’(S10) 
 
 
 
• Lack of concern about methodology and statistic course 
 
The RCT as an experimental method is new to those clinicians who graduated from 
medical school more than 20 years ago. From their descriptions I found the 
discrimination in medical school that students and teachers are concerned with all 
clinical subjects, but not epidemiology or medical statistics, which is in line with the 
Chinese culture and Chinese social hierarchies. Surgeons are a group receive the most 
respect because they could perform operations, save patients lives, and in the war they 
could join the army immediately; followed by physicians, who are considered as skilled 
people who can help patients in daily life, old (that means experienced) physicians are 
also admired by patients; and then the third kind of people who worked in hospitals, but 
do not conduct clinical jobs, are epidemiologists or medical statisticians.  
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Another reason is the difference in financial income. Given the strong link between 
clinical work and financial income, Surgeons are an unbeatable group to receive more 
grey incomes, because they would be the direct person to make effect on patients’ 
bodies, followed by physicians, but not epidemiologists or statisticians. Therefore, these 
people are not working in hospitals, and so could not help professional clinicians when 
conducting research work. 
 
Those clinicians whom I interviewed in hospital are all good at clinical practice. They are 
concerned about clinical skills much more than research design. Especially those 
clinicians who graduated from medical school 20 years ago; there was no relative 
training course on research methodology available from medical school at that time. On 
the other hand, randomised controlled trials as a new method was introduced to medical 
research just about 30 years ago. Chinese senior clinicians may not take enough 
concern on RCT research methodology. 
 
4.3 Discussion 
 
This is the original research about Chinese clinicians’ understanding and attitude toward 
RCTs.  I found the use of focus group meeting is quite suited for my research, because 
without the group circumstance, junior clinicians would not like to talk more details of 
their RCT experiences. In my focus group meeting, clinicians are from different 
department, they are quite excited to hear from their colleague of different department 
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on conducting RCTs, some recruitment experience and reward information they would 
like to share with others.  
 
When I asked junior doctors whether they would like to participate as a researcher in a 
randomized controlled trial, most junior clinicians responded that they would, for 
example,  ‘yes, I like to participate in randomized controlled trials, because this is a 
good opportunity to learn what is the most advanced technology or treatment of the 
disease area.’ ‘I could learn from the randomized controlled trial about their research 
design and some research methods.’ ‘Participating in randomized controlled trials would 
bring me more research experiences, and learn more advanced research methods.’ 
Therefore, from their opinions, I found that most junior clinicians mentioned that they 
could learn through the trial, about new techniques, advanced treatments and research 
strategies. Even some junior clinicians who would contribute their working time to 
complex and trivial tasks, but junior doctors are still consider this is a good opportunity 
to gain research experiences.  
 
• Good reputation and social status 
Doctors’ good reputation is based upon their research and clinical achievements. In 
order to be promoted to a senior member in the hospital, publications in high quality 
medical journals are essential requirements. Although there are debates about this strict 
requirement, this has been a basic requirement for medical doctors, for at least the last 
20 years and has had an impact on all Chinese doctors. 
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Their clinical experiences and skills are enhanced during their daily work. Based on the 
large population of China, the number of patients in this country is substantial as well. 
Chinese patients often prefer to go to famous hospitals in bigger cities. Therefore, the 
patients of Guangzhou hospitals include not only local citizens, but also patients from 
the surrounding rural areas and undeveloped provinces nearby, such as Guangxi and 
Guizhou. 
 
Junior doctors commonly enjoy a high social status, often combined with expectations 
of a high and stable income and job security. Although they are not senior doctors in the 
hospital, they believe that through their hard work they will be promoted to senior status 
in the future. On the other hand, doctors as a professional group have always been 
considered as a high social class in Chinese history. Even through difficult times, for 
example, in 1950’s most of the Chinese medical clinicians were ‘barefoot’ doctors, but 
they were considered experts with the most medical knowledge in their village, and they 
were considered to save peoples lives. They were farmers who received minimal basic 
medical and paramedical training and worked in rural villages in the People's Republic 
of China to bring primarily health care to rural areas where urban-trained doctors would 
not settle84.They promoted basic hygiene, preventive health care, family planning and 
treated common illnesses85. (The name comes from southern farmers, who would often 
work barefoot in the rice paddies.)  
•  participating research activity 
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In my study, I interviewed senior doctors from Guangzhou. They had the choice of 
deciding whether to participate in a medical study or not. Those senior doctors all had 
experience of conducting medical research, but few had worked on randomized 
controlled trials. I think the main reason is that randomized controlled trials are complex 
experiments that involve teamwork, especially if they are multi-centre projects. In my 
research, I have found that most randomized controlled trials were organized by big 
institutions from Beijing and Shanghai, this may be because those institutions have 
larger research teams than in other cities. 
 
In my study, my interviewee doctors had been involved in randomized controlled trials 
as partner leading researchers, who were in charge of recruiting patients and 
conducting trials in Guangzhou, but not involved in the trial design, quality control, data 
analysis and resulting report. 
 
When the hospital was invited to take part in a randomized controlled trial, the host 
institution would set up a meeting to introduce their study proposal. Senior doctors 
would be invited to the meeting to discuss whether they would like to participate. Senior 
doctors would judge the feasibility of the study from their personal experience: the 
effectiveness of the drug / treatment, the acceptability of the patients and the impact on 
medical workers. In addition, the financial and academic reward is a consideration to 
senior doctors. Once the senior doctor decides to participate in the RCT, then their 
department would have another introduction meeting, but the main target of that 
meeting is to allocate research work to each clinician. 
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Junior clinicians are clinical and research team members in their department. Some of 
them will view outpatients in clinic, and also join their colleagues taking care of 
inpatients in the wards. They are the people doing a substantial amount of work and 
working inflexible hours.  Although they are not the lead within the department, once the 
team leader decides to do some research, junior clinicians will deal with the detail of the 
research. In addition, senior doctors would carry out important operations or treatments 
for patients, but junior doctors carry out all routine works which are basic but substantial 
and important procedures to patients. Similarly to clinical practice, junior doctors are 
also doing substantial work in research as well, for example enrolling patients or 
recording data. 
 
• Clinicians’ working profile 
 
The senior doctor is the core person in the department and leads the team. From my 
observations, I found that senior doctors are always followed by junior doctors because 
they are reporting update information on patients and looking for changes to prescribing. 
On encountering difficult cases, junior doctors are accustomed to consulting senior 
clinicians. Therefore, senior clinicians not only take care of their own patients, but also 
patients from junior clinicians. In addition, senior clinicians are invited as consultants by 
different departments and different hospitals. They are considered experts in their 
clinical area. 
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Senior doctors are not only the chief of clinical practice, but also the leaders of medical 
research.  They take the lead role in medical research and hold academic titles as 
professor or assistant professor. In addition, they are required to produce a certain 
amount of publications each year. In order to get promoted to a senior and research 
position, doctors should have at least 2 publications in high impact factor medical 
journals. Once they are appointed to senior level they need to maintain their good 
reputation and seek further promotions, and high-quality publications are a substantial 
and necessary requirement in achieving this. 
 
• What are the factors that facilitate junior clinicians’ participation in research 
work? 
 
From my research I found  
1. Collective activity. Junior clinicians are in the department as a group member, he 
or she has the awareness of collectivity. As an individual, he or she should comply 
with the group rules (i.e. the rules of their department, hospital, profession, culture 
etc), which is a common psychological impact from being a member of a group or 
organization. Normally the leader of the department decides to participate in clinical 
research, however, the leading member is also the junior clinician’s supervisor as 
well, therefore junior clinicians usually choose to comply with their leader’s decision. 
Even if they can’t get any direct benefit from the research they could be rewarded by 
the supervisor’s good impression of them. 
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4 Financial reward.  To be involved in some research, especially randomised 
controlled trials, junior clinicians could receive some financial rewards from the 
research organizer or pharmaceutical companies. This is a possible reason for 
participating in research, however from my study I found that clinicians are not 
generally satisfied with this research income. 
 
5 ‘Collective reputation’, almost every junior clinician I interviewed mentioned this. 
They believed that the good reputation of the department would be potential wealth 
for their department and individuals working within it.  This indirect benefit from 
research was considered a very important issue by junior clinicians.  
 
On the other hand, there are also some junior clinicians who do not like to participate in 
randomized controlled trials. As I mentioned before, to work in a Chinese hospital, the 
Chinese clinicians’ workload of viewing outpatients is heavy. Clinicians, who work in 
clinics, have to view 20- 50 patients in every session (a morning or an afternoon, about 
4 hours). Therefore, they are very busy in clinic and are also busy in wards. They need 
to take care of in-patients and monitor their disease progress each day. If they agree to 
participate in a randomized controlled trial that means they should spend more time on 
the concerns of those patients eligible for the research study, and recruiting them to 
take part. This can be quite time-consuming for clinicians because adhering to 
randomized controlled trial regulations means that they need to clearly explain the 
research proposal to patients.  Some junior clinicians complained to me ‘I prefer not to 
recruit patients compared to the limited financial reward’ ‘the financial reward is so little, 
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I prefer not to participate, because spending so much time on it isn’t worth it. But that is 
my department research project, so I have to do it. From a financial perspective, it isn’t 
worth it.’ 
 
Patient complaints could be another barrier preventing junior clinicians’ involvement in 
clinical trials. Clinicians mentioned that their main aim in being a medical doctor is to 
treat patients. Without medical research, they believe they could best treat patients 
based upon their personal clinical experiences, or, for difficult cases, call for senior 
clinicians’ opinion / consultation. Therefore, junior clinicians believe they did not get 
complaints as much as if the patients were involved in a trial, because they give their 
patients proven efficient treatments.  
 
Clinicians are not only doing randomised controlled trial research; clinical reports, case 
reports, case control, cohort or cross sectional studies are also potential research 
methods they could manage.  Even some clinical practice could be reported as case 
series which are quite good research methods as they are easy to handle and there is 
less use of statistics. Furthermore, randomised controlled trials require a large patient 
population and the trial quality requirement is strict, which makes it hard for an individual 
clinician to set up. On the other hand, the funding of randomised controlled trials is 
relatively large.  Therefore, individual clinicians in Guangzhou are always involved in 
trials as patient recruitment leaders. This is another conflict, because the senior 
clinicians are used only as recruitment leaders in their local area, but not used in 
conducting the pivotal work in trials, so they are not first or second author of the 
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research publication.  They would not care about a paper with his/her name as 5th or 6th  
author, which deters them from participating in RCTs. I quite understand that 
Guangzhou clinicians prefer to do other types of research more than randomised 
controlled trials.  
 
In the recent year, press and media coverage is not supportive to Chinese clinical 
trials86-88. Improper research proposals and unfair issues in past medical research trials 
have harmed patients’ rights.  Educated patients do not like ‘medical research’, because 
they have heard so many bad stories about research. If they participated in a 
randomised controlled trial, they worry about their situation. They may link any 
discomfort or untoward event to a medical accident. Patients’ complaints and special 
requirements increase junior clinicians’ workload, which annoys clinicians. At least 10 
junior clinicians complained to me about their patience of research. ‘Sometimes I feel 
regret to involve some patients in a randomised controlled trial. If I know they were 
fussy guys, I prefer not to take the recruitment reward (financial reward) and not get 
them involved.’ 
 
4.4 Conclusion  
Chinese clinicians need more encouragement on conduct RCT research from Chinese 
medical system. Junior doctors require more practice in RCT work another than 
recruitment only. The work-load pressure and traditional Chinese culture made 
clinicians are in dilemma of being a medical doctor or a researcher. Chinese clinicians 
also need to improve their knowledge of RCTs. 
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Summary 
In this chapter I made comparison between Chinese and Western clinicians on their 
answers of physicians orientation profile, detected what are the differences and then 
interviewed senior and junior doctors. I described clinicians’’ routine work and research 
activities and examined the differences from Chinese culture and current Chinese 
medical system.
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Chapter 5.  Chinese Patients’ experiences of randomized 
controlled trials 
Outline 
In this chapter, I present another study of experienced RCT participants, about their 
understanding and attitude towards RCTs, Because they would influence clinicians and 
then the RCT quality in an indirect way. This chapter and chapter 4 are both trying to 
explore the barriers of Chinese RCTs. 
 
5.1 Method  
Patient recruitment was discussed with individual clinicians during the clinician 
interviews or focus group meetings. After discussion, clinicians suggested they 
introduce me to their patients and explore whether they would be interested in 
answering my questions.  All involved patients gave their consent and half of recruited 
patients had previous experience of participating in a randomised controlled trial. 
 
Patients, as the main research subjects are important to the quality of randomised 
controlled trials. Their understanding and attitude would reflect the clinical trial in many 
ways. I conducted personal interviews with patients, whom I met in First Municipal 
People’s hospital of Guangzhou, No. 12 hospital and Red Cross hospital; I contacted all 
my interviewed clinicians, and recruited patients with their help. I was introduced to 
patients by those clinicians and I interviewed eligible patients whilst they were waiting to 
see doctors.   
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The patient’s experience of randomized controlled trial is my first concern. Therefore, I 
contacted those departments carrying out randomized controlled trials at that time, and 
tried to contact their recruited participants. Although most patients had no experience of 
RCT, they could be a potential RCT participant; therefore I conducted interviews with 
them as well, if they had heard of an RCT before. 
 
5.2 Research question 
I aimed to explore the patients’ understandings and personal experiences of 
randomized controlled trials and to identify the barriers to participation in clinical trials. 
Therefore my research questions are; 
1. What is a randomized controlled trial? 
2. What is your personal experience of randomized controlled trials?  
3. What are the reasons for patients preferring to participate in randomized 
controlled trials? 
 
Patients interview questions 
1. Can you describe what a randomized controlled trial is? 
2. Can you describe what informed consent is? 
3. Do you trust your doctor will give you the best treatment? 
4. Do you prefer the doctor to make a decision for you or you and your doctor to 
make the decision together? 
5. What is your personal experience of participating in a randomized controlled trial? 
 
5.3 Results 
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132 experienced patients were contacted, 82 of them refused interview, 50 patients 
completed an interview. In 82 of refused cases, 23 of them said they were busy and 
short of time to participate; 25 of them said they did not participated in any RCT, just 
routine treatment; the rest 34 of them said their clinicians knew everything, I should ask 
their clinicians instead of themselves. 
 
• Age and sex 
Interviewed patients age ranged from 17 to 66, mean is 47.5, median is 52. There were 
more female (66%) interviewees than male (34%);  
 
• Understanding of randomised controlled trial  
 
I found compared to ‘randomised controlled trial’, ‘medical research’ is a more 
understandable and acceptable term for patients, whether they had experience of RCTs 
or not. When I mentioned ‘randomised controlled trial’, patients stumbled over their 
words. That maybe because clinicians use the term ‘medical research’ to discuss their 
RCT projects with patients. 
 
I found that none of my interviewees could accurately describe randomised controlled 
trials to me.  Most of my interviewees just shook their head and said ‘no, I do not know.’  
A few of the interviewed patients said ‘my clinician told me there is a new medicine 
which maybe fit for me, they invite me to the medical research , because I could have 
chance to use this new medicine free.’(P35) ‘My clinician told me, they have a medical 
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research which included 2 different medicines. If I participated in, I can use one of them 
free. However, my clinician does not know which medicine I am using, I just believe my 
clinician would not harm me, he would choose the best treatment for me’ (P43) 
 
 
• Randomisation 
I think patients interviewed had a limited knowledge of randomization.  Even patients 
who are involved in a trial could not describe randomization.  These details were 
ignored by clinicians when they recruit patients into the study. Randomization is not 
considered an important factor to patient recruitment. Therefore, involved patients are 
not clear about this concept. 
Most interviewed patients said ‘I do not know’. One interviewee said ‘clinician choose 
one group for me, I know maybe the decision is not from my clinician but from other 
clinicians in this hospital.’(P20) Another patient told me ‘clinician said we were 
randomized to choose for different treatment groups, which was decided by the 
computer. I believe computer scientific arrangement. (P31) 
  
• Blinding  
I think all my interviewed patients had a good understanding of blinding; From the 
patients point of view, they found it difficult to understand that the clinician was blinded 
in a randomised controlled trial. More than half of my interviewed patients told me that 
they do not believe that their clinician had no idea about allocation, even in trials which 
are multi-centre and double-blind.  The reality is that clinicians do not know patient’s 
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allocation, however patients consider blinding is a clinician’s trick.  For example, one 
patient commented, 
‘My clinician told me he doesn’t know which group I was in, but I do not think so. He told 
me only a small group of people know that, we need wait until they finish the trial. I think 
they are all in the same group.’(P2) ‘My clinician told me he doesn’t know, but how 
could it possible? Even my clinician does not know, but his supervisor would know. 
Therefore, my clinician would know which drug I am using.’(P6) 
 
• Understanding of Research uncertainty and equipoise  
 
In randomized controlled trials, uncertainty is the main reason for setting up research 
and then which would cause varied result, although trial designer tried to give equipoise 
to all patients. I had discussed this question with patients: ‘Do you believe there are 
some uncertainties in medical research?’ they all replied to me that they understood that 
there are uncertainties in medical research, but they can’t believe that uncertainty would 
impact upon them, especially comparing a new drug to placebo treatment; they can’t 
understand the equipoise between groups. Although I explained the principle of 
randomised controlled trials, which is based on medical uncertainty, all of my 
interviewee patients refused to accept it, with explanations such as ‘if the clinician is not 
sure about the effect of that drug, he would not use it on patients.’(P41) ‘I believe, 
before the drug is used on patients, they must have very strict research. This new drug 
is safe.’ (P42)‘I can’t believe the clinician would allow use of a placebo on me. Clinicians 
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bear responsibility for my disease, I do think he will try his best to help me recover.’ 
(P25) 
 
I have no idea about how to make patients understand medical equipoise, which is not 
difficult to explain, but when patients talk about this on their personal medial condition, 
they tend to ignore and refuse to think about this question. The reason for this 
phenomenon could be linked to Chinese patient’s unique trust in medical doctors, which 
I will discuss later.   
 
• Free drug attraction 
From my research, I found free drug treatment is available in all Chinese randomised 
controlled trials, which was supported by pharmaceutical companies. Usually 
pharmaceutical companies are the organizers and sponsors of randomised controlled 
trials; after all, most trials were conducted in order to apply for a drug licence?  From my 
research, clinicians told me that ‘free drugs’ were attractive a couple of years before, but 
because people have heard increasing bad news about free drugs, that this no longer 
works. Patients are active in current clinical trials, although increasingly patients are 
seeking help from other resources rather than clinicians, for example, consulting experts 
or checking the internet. However, to those patients with poor economic conditions or 
from rural areas, free drugs are still attractive, although the number of poor patients has 
decreased.  
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Patients describe free drugs as ‘if the drug is free, I will think about it more carefully. But 
if my clinician told me to take it, I would. But I do not think free drugs are attractive to 
me.’ (P23) ‘My clinician told me that this drug is free, I feel lucky, although I need to give 
4 blood samples. But I think it is good for clinicians to understand my health 
condition.’(P31) ‘My clinician suggested I take that drug, with his recommendation I 
would like to use it, and save quite a lot of money.’(P32) ‘It doesn’t matter whether the 
drug is free or not. We patients come to the hospital for the best treatment, no matter 
how much we should pay’(P34) ‘there is no free lunch in the world, when I was 
introduced to using a new drug, I checked it through the internet and consulted other 
clinicians and later I accepted, because many doctors agreed to me using 
it.’( P48,P49,P50) 
 
Free drugs are welcomed when patients are experiencing difficult economic times. 
However, with the development of the Chinese economy, people are increasingly caring 
about their health rather than economic cost.  
 
• Patient-doctor relationship in patients description 
 
The patient-doctor relationship plays an important role in medical treatment89. A good 
relationship combined with trust and friendship has a more beneficial psychological 
effect than medical treatment alone90. the quality of the doctor-patient relationship can 
affect diagnosis, treatment and recovery and there is a correlation between effective 
doctor-patient relationships and improved health outcomes91-93. Chinese patients 
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appreciate their relationship with their clinicians, because they know that when they are 
facing clinicians, they are individuals but clinicians are more like a group. The cost of an 
accident for a clinician could be rigorous criticism, and even a revoked medical licence, 
however, for individual patients, that cost is their personal health or even their life, which 
is not affordable. 
 
I asked patients ‘how is your clinician? Did he/she treat you well?’ all nodded with a 
serious face and 100% of patients answered ‘yes’. I asked why they said yes and they 
described ‘my clinician treats me very well. I am very appreciative of his medical 
treatment. On the other hand, he inspects wards everyday. I could find him every time I 
want. I can crack a joke with him, and he will play back as well. He is a nice 
man.’(P2,P3,P14,P15) ‘My clinician treats me very well, he checks my body very 
carefully and answers my questions patiently.’(P20, P21) 
 
• Chinese patients’ Decision making 
Uncertainty is quite a difficult concept to Chinese patients; they find it difficult to believe 
that clinicians have uncertainty in routine medical treatment. Thus from patients view 
they have never thought about their personal decision making patterns before. I asked 
patients ‘have you participated in decision making for your own treatment?’ almost 
100% of my interviewee patients said ‘no’. Only one of my interviewees thought for a 
while and said ‘a few years ago, when my wife was going to give birth, that clinician had 
asked us whether we prefer abdominal delivery or natural labour? That is the only one I 
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could remember the clinician discussing medical issues with me. But I asked in reply to 
that clinician, and followed her advice to do natural labour.’ (P13) 
 
I asked them ‘if you had the opportunity to make decisions for your own treatment, 
would you like to make decisions with your clinician or let your clinician make the 
decision for you?’ To my surprise, 100% of my patients said ‘I would prefer my clinician 
to make the decision for me’. The reasons given were; 
 
‘Clinicians are the professional people in this area’. (P12) ‘Clinicians are certain to have 
more professional knowledge than me in this area’. (P18) ‘They (clinicians) are all 
experts in this area. I come to hospital to seeking their help, or I will stay at home.’(P35) 
 
• Clinicians elicit high levels of trust 
AThrough my research, I found Chinese Patients are extremely trusting of their 
clinicians which is maybe unique around the world.  100% of my interviewed patients 
said they trust their clinician to provide the best treatment to them, even if they are in a 
randomised controlled trial. One of my interviewee patients said ‘if I do not trust my 
clinician I would not come to hospital.’(P5) Several patients echoed these words. I 
believe Chinese patients have a high level of trust for their clinicians. However, there 
has been no comparative research into patient trust in clinicians among countries 
conducted before. 
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5.4 Discussion  
 
• Conflict: Informed consent or extremely trust in clinicians 
Through my study, I found Chinese clinicians are not like their colleagues in Western 
countries, they did not get annoyed by getting patients’ signature on informed consent.  
From Western literature, I found Western clinicians were bothered by the time-
consuming nature and impact of doctor-patient relationships. However, Chinese 
clinicians do not worry about those issues at all.  
 
Most of my interviewed patients said they joined the randomised controlled trial because 
they trust their clinician. I think the Chinese doctor-patient relationship is different to 
Western style and this is because of the history and cultural context in China.  I tried to 
explain clinicians’ uncertainty of their clinical practice to patients, but I found that 
patients did not understand or do not accept that clinicians have uncertainties in their 
clinical practice. When I asked patients whether they trust their doctors, they answered 
‘of course, if I don’t trust these doctors, I would not come to hospital.’ ‘This is a big and 
famous hospital, I think all of here clinicians are very good at clinical practice, especially 
those senior doctors.’ When I explained that clinicians may have some uncertainty 
about their clinical treatment, most of my interviewed patients said ‘really? Oh maybe, 
but I still think clinicians would do their best and give me the best treatment.’ ‘I believed 
they are all expert in this area.’ ‘I think the doctor let me sign on the file (informed 
consent) because he thinks that would be good for me’ 
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On the other hand, the population of Chinese patient is large, clinicians meet new 
patients everyday, only a very few of them would call back. Therefore, clinician are 
not concerned about the clinician- patients relationship of the future. This is maybe a 
difference compared with Western countries. 
 
• A typical case of informing patients and getting their signature  
I observed the whole course of DR. W and Patient Mr.J conversation, afterward I 
interviewed Mr. J. However, I found that Mr.J’s understanding of informed consent was 
quite different from what he had been told. The Clinician introduced their randomised 
controlled trial project to the patient. This particular project was about a new drug 
compared with a placebo, in a double blind, randomised controlled trial. Therefore, 
neither clinician nor patients know the allocation. The clinician describes the 
randomization to patients as ‘you may receive the new drug or you may receive the 
placebo, this is decided by the computer. We clinicians do not know which group you 
are in either. This new drug passed Phase 2 trials with very good results, but we are not 
sure whether it would be good for all common patients.’ The patient had a quick look at 
the informed consent, and signed his name at the end of the sheet.  
 
After the clinician left, I asked the patient ‘what is the main reason for you taking part in 
this research?’ he answered ‘I believe the doctor would treat me the best way.’ I 
reminded him that the clinician had said he put the patient in an uncertain group. But the 
patient replied ‘I trust the doctor. He is very nice, since I was in the hospital he was quite 
careful and responsible to me, I am appreciative. I trust his decision’.  
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This special doctor-patient relationship is one of the potential reasons for the ease and 
large quantity of patient recruitment in Chinese RCTs. At the beginning, Chinese 
clinicians enjoyed the convenience of recruiting patients by using the special 
relationship; however, later they have suffered in this relationship as well, because 
patients expected a certain positive result but that can’t be guaranteed in RCT. When 
adverse incidents happen, frontline clinicians are the people who have to face the 
consequences.  
 
Informed consent is a legal condition whereby a patient can be said to have given 
consent based upon a clear appreciation and understanding of the facts, implications 
and future consequences of an action. Informed consent was accepted as not only a 
clear statement of the research, but also the memorandum for patients and clinician. It 
is showing the contemporary acknowledged medical relationship between clinicians and 
patients in research. However, this kind of statement was not recognized properly within 
Chinese patients, maybe that is also problematic with Western patients..  
 
Normally, in an informed consent, it should present not only the research background, 
subject and method, but also the researchers’, hospital’s and the patients’ responsibility. 
Furthermore, in case of accident, what and how they treat and who takes responsibility 
is also stated clearly. From my study, I found that clinicians welcome this detailed 
informed consent. Because there are some accidents that have happened before, and 
patients complained they were cheated by clinicians into participating in a clinical trial. A 
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signed informed consent is the only legal evidence for public judgement. Most clinicians 
told me they prefer a detailed informed consent, which could protect both patient and 
clinician’s rights in research. Some patients suspect any uncomfortable reactions were 
caused by participating in the medical trial, rather than caused by their disease 
progression. A detailed informed consent would help frontline clinicians protect their 
interests in this case. 
 
 
5.5 Conclusion  
Traditional Chinese culture has had an effect on Chinese patients. Not only in RCT but 
in all medical activities, patients are passive objects. Chinese patients need to improve 
a lot on their self-determination, however, which would involve fundamental changes to 
Chinese society. Chinese patients are lack of the consciousness of self-determination in 
patient-doctor relationship. They used to rely on medical clinicians to make decision for 
them that is the traditional pattern of doctor-patient relationship, but not fit for current 
medical circumstance any more. In order to protect patients’ benefit, healthy doctor-
patient relationship and quality of RCT conduct, patients need to learn playing 
independent role in the relationship, not only in RCT research, but all medical activities.  
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Summary 
In this chapter, I described the research of Chinese patients’ knowledge and attitude to 
RCTs. The influence from patients is also important to the conduct of RCTs. With the 
result from chapter 4, I discuss several conflicts which are existing in current Chinese 
medial society, and which are the barriers of blocking RCT conduct. 
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 Chapter 6.  Discussion 
 
I have conducted a substantial original study concerning quality of RCTs conducted in 
China, and the attitude of Chinese clinicians and patients toward RCTs. Although RCT 
have been conducted in China for around 20 years there has been no comparative 
research focussing systematically on Chinese RCT quality. The RCT as the ‘gold 
standard’ research method has become widely used in Chinese medical research, 
however, inadequate reported information and biased results limit Chinese RCT quality, 
and lead to rejection from the world medical society.  
 
I have identified that reporting of RCTs in China requires substantial improvement to 
meet the criteria described in the CONSORT statement. The conduct of Chinese RCTs 
cannot be directly inferred from the standard of reporting; however without good 
reporting the methods of the trials cannot be clearly ascertained. Research bodies in 
China should ensure that the reporting of RCTs is improved to meet internationally 
agreed standards, thereby allowing the conduct of their studies to be monitored and 
encouraging high quality standards. 
 
In addition, from my analysis comparing the results of Chinese RCTs with those from 
other counties, I found Chinese RCTs biased.  
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I have also conducted original research on Chinese clinicians and patients’ attitudes 
toward the RCT.  It seems likely that the understanding and attitude towards RCTs by 
those involved in their conduct as subjects or investigators may have a substantial 
impact upon the manner in which RCTs are conducted and reported. The RCT as a 
research method, developed in Western countries, and is historically located in the 
Western medical system and social background. Chinese medical professionals and 
Chinese medical culture are different to that in the West; therefore Chinese RCTs may 
have some specific characteristics.  In order to improve the conduct and reporting of 
Chinese RCT we have to understand Chinese medical society and Chinese medical 
culture. Chinese clinicians’ experiences are different to those of clinicians in the West; 
therefore, we should consider that they need specific strategies of encouragement to 
improve their RCT work. Western clinicians’ experiences are helpful, but may not on 
their own be sufficient. 
 
More training and education should help improve Chinese physicians and patients’ 
understanding and conduct of RCTs. The stage of population development may also be 
another factor for the current state of RCT practice and reporting. 
 
 
Frequent medical academic publications benefit to Chinese clinician’s career much 
more than Western clinicians’, which is a significant founding through questionnaires 
survey. This result is confirmed by my following quantitative research. Clinicians 
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complained participating in RCT was not benefit to their academic publication or any 
other reward other than financial income. The only standard of Chinese clinicians’ 
research work is their publications; this evaluation standard is sole. These made 
clinicians (most of them are junior clinicians) feel they are wasting time when they 
participate in RCT, such as recruiting patients and explaining protocol to patients. 
Therefore, this made effect to Chinese clinicians on their attitude to participating RCTs. 
 
In addition, Western clinicians may consider that patients’ rights to select treatment 
options are more important than scientific knowledge advancement, but Chinese 
clinicians do not.  In my subsequent qualitative research, I also found Chinese clinicians 
prefer to make decision for patients, and Chinese patients prefer this pattern of decision 
making rather than their autonomy, this is a Chinese specialized doctor-patient 
relationship. Cong’s study also demonstrated the difference in doctor-relationship 
between China and Western countries94. The reasons for this kind of relationship are 
discussed below. However, in the context of the RCT, patients should be independent 
to their clinicians; therefore, a brand new doctor-patients relationship should be build on. 
This is not an easy and fast process, which is opposite to Chinese traditional doctor-
patient relationship.    
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6.1 Inadequate report and publication bias 
From my study I found that the standard of reporting of trials was generally poor, 
inadequate information of RCT were reported, for example nearly two-thirds failed to 
report any information on their methods of randomisation; none of the trials discussed 
allocation concealment. Those inadequate reports of such essential trial information 
demonstrated that the quality of Chinese RCT papers needs to improve. In addition, the 
failure to prespecify a primary outcome measure may lead to the inappropriate 
application of apparently positive results from trials when in fact chance alone may often 
provide an adequate explanation for the observed results. 
 
Publication bias appears prevalent in Chinese RCT publications. From my research, I 
found Chinese RCTs reported fewer outcomes than Indian and Western papers, but 
with high rates of positive results reported. Those outcomes with non-significant results 
appear frequently to have been omitted in the final report. In addition, I found the 
outcomes described in the methods and results sections did not match in many Chinese 
RCT papers. All of this evidence strongly indicates publication bias in Chinese RCT 
papers. 
6.2 Clinicians dilemma in conducting RCTs 
Traditional culture makes Chinese clinicians more willing to be a medical doctor rather 
than a researcher, which has an effect not only on clincians but also on medical school 
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students. The basic statistical principles, which are important to RCTs, are largely 
ignored by Chinese clinicians.  
The RCT as a research method was developed in Western countries, providing 
unbiased evaluation of medical interventions. However, when the RCT method was first 
introduced to China, the different culture and social background may have undermined 
the quality of the conduct of RCTs which I discussed in chapter 4. The unique doctor-
patient relationship and high levels of patients’ trust could prove damaging to both 
clinician and patients, because in context of randomized controlled trial and elsewhere, 
clinicians do have limitations of knowledge, attitudes and abilities, naïve patient trust 
has possible limitations and disadvantages for patients. 
Chinese senior clinicians are the leading group in clinical practice and medical research. 
They have adequate knowledge about conducting a proper RCT, and participating in 
RCT research. However, senior clinicians are not the people who directly conduct RCTs 
in practice, which instead are undertaken by junior clinicians who are in charge of 
recruiting patients, getting their informed consent and taking care of patients during 
RCTs.  
 
Financial rewards are another incentive to push clinicians to go further on their clinical 
practice but not medical research. The rationale for conducting medical research among 
junior clinicians is weak, which needs to be rectified.  
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From my research, I found junior doctor are in need of more encouragement for their 
research work, their motivation and their work quality appears highly correlated. 
Currently, they only receive limited financial reward as a result of conducting RCT, but 
that is not considered as important issue to junior clinicians. I hope Chinese medical 
professionals including medical editors will take on board the findings of this research 
and make some changes on their daily work that improve the quality of RCT conduct 
and publication accordingly. Below are listed some suggestions I summarised from my 
interviews: 
1. Link conducting RCT research to junior doctors work performance and 
progression 
2. Provide ongoing research methodology training in hospitals 
3. Make research data available to junior doctors, and encourage them to write a 
research paper if they have good idea 
4. Ensure editors in medical journals have received suitable training in research 
methodology  
5. Make the CONSORT statement as the essential RCT report standard of medical 
journal national wide 
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6.3  Conflict: Clinical doctor and researcher 
 
Compared to Western clinicians, Chinese clinicians are significantly more motivated to 
work as a medical doctor rather than an academic researcher, althrough Western 
clincians are also facing the same dilemma78. Chinese clinicians all have substantial 
experience of clinical practice; I believe that every senior clinician could be called an 
expert in their own area. Compared with conducting research, clinical practice brings 
clinicians more praise from patients and greater financial return, which are direct and 
visible benefits.  
 
Research could help Chinese clinicians enhance their reputation in a certain medical 
area, but they still believe research is a supplement of their clinical work, not their main 
objective. Clinical work is their main target forever. The reasons given for this interest 
included: social responsibility; personal interest and as a requirement for promotion. 
 
‘I am already a professor; I do not need to get any promotion. What I do will just help the 
development of medical science, not only for Chinese patients but also for all 
populations in the world. We are doing diabetes research, which is quite complicated; 
but any small progress would help human beings in preventing diabetes.’ 
 
‘I have been doing diabetes research for a long time. I worked in this department for 25 
years, my PhD is about this topic as well, and any relative research about this topic I am 
still very interested in. yes, I love any research on diabetes.’ 
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‘I am assistant professor at the moment; I need publications to obtain promotion. This 
research is about a new medicine, I discussed with the project manager about whether 
could I share their final data to write some papers, and they agreed. I asked on other 
research projects, not just randomised controlled trial research, but most of them said 
no. So I am quite pleased to do this project. Although I know it will be hard in data 
analysis later, but it is good to have final data.’ 
 
6.4 Conflict: traditional Chinese doctor’s role and modern clinician’s role  
 
As a medical doctor, the traditional image is a knowledgeable and busy person working 
in clinic. Personal knowledge and experience are the most important issues of taking 
this role. At that time, people preferred to judge a clinician’s ability though their 
appearance: older doctors were considered experienced and knowledgeable, especially 
for doctors practising traditional Chinese medicine. Chinese medicine is much more 
reliant on experience rather than medical knowledge94. Nowadays, since the Internet is 
increasingly used in medical work, clinicians are involved in bigger teams, not only 
working with colleagues in their own hospital, but also with clinicians in their field around 
the world, including bio-scientists or pathologists. The internet has enabled individual 
clinicians to be linked around the world. Progress in each medical area can be reported 
rapidly. Easier communication means that co-operation across countries or a province 
is more feasible.  Therefore the traditional clinicians working pattern was broken.   
Clinicians not only have to concentrate on their current patients, but also on updating 
                                                                                                                              162
their medical information, including possible treatments and effects of other treatments. 
If clinicians are just working in clinic with their patients without checking recent medical 
information, this clinician cannot be considered to be a qualified clinician, because it is a 
present requirement that modern clinicians should keep up with scientific developments. 
 
There are substantial training courses about IT skills, research methodology and 
statistics provided by Chinese medical schools currently. However, my interviewee 
senior doctors had graduated at least 20 years previously.  At that time, they were only 
expected be good at clinical practice, but with social development, the requirements for 
clinicians have changed as well. Senior doctors did not receive enough training in 
research when they were in medical school; however many have caught up by 
themselves in their daily work and learnt to update information for themselves. 
 
6.5 Traditional doctor-patient relationship needs to be changed 
Although Chinese medical society accepted Western medicine and health service, 
however, the relationship between doctor and patients are still kept as traditionalised: 
patients rely on clinicians completely, patient and doctor are not equal in the relationship, 
doctors are demanders and patients are negative acceptors94. In this relationship, 
patients consider doctor as their representative, and doctors used to make decision for 
patients. However, RCT as a modern medical research method which based on 
Western medical circumstance, patients and doctors are equally and independently. 
This is the basic understanding of informed consent and patient allocation. In my focus 
group meeting and interview, I found clinicians are confused about this conflict. They 
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spend lot of time trying to explain the research protocol, and ask whether patients would 
like to participate in, but most patients said ‘you make decision, I trust you’. When ask 
for their signature on informed consent, most patients fear to take responsibility by 
themselves, and withdraw at the beginning. If Chinese doctor-patients relationships 
could be adjusted, I believe the conduct of RCT would be improved in many ways: 
clinicians could save time on explain protocol and have written informed consent; 
eligible patient would be easier to recruitment than before.   
 
From Cong’s study, he remind in Chinese medical relationship, the Western Patient-
doctor relationship was replaced to chinese patient-family- doctor relationship, which 
was the consequence of Chinese traditional culture94. Therefore, to explore a new 
patient-doctor relationship in Chinese society is in need. 
 
 
 
6.6  Ethic issues 
The reporting of ethical issues was inadequate in Chinese RCTs. Fewer than 11% of 
the trials reported having ethical committee approval, although the latter is a legal 
requirement in China59. Also, only a minority of the Chinese studies (17.4%) gave 
adequate details about the informed consent procedures; a few mentioned that 
participants attended of ‘their own free will’ but the remainder made no mention of 
consent. However, this level appears better than in a recent review of traditional 
Chinese medicine trials57;59.   In my study, I found significant shortcoming in the 
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reporting of ethical issues in Chinese papers. Informed consent and ethical committee 
approval are widely accepted as fundamental requirements of conducting RCTs in 
China but not all hospitals involved in trials have institutional ethical committees64 . 
From my interviews, I found ethical issues were considered an important procedure in 
starting an RCT in China. The Helsinki Declaration is known by all qualified hospitals 
undertaking RCTs, whose researchers understand that having approval from an ethical 
committee is a necessary precursor to conducting RCT. 
 
In the Chinese cultural context, it is not difficult for Chinese clinicians to get patients’ 
signature on informed consent.  Because of the unique Chinese doctor-patient 
relationship, patients place substantial trust in their doctor. However, increasingly, 
Chinese clinicians have found that this convenience is not so helpful, but instead may 
harm their reputation among their patients. The RCT is a research method based on 
uncertainty, which undermines the basic image of the traditional Chinese medical doctor. 
Therefore, it is important that Chinese clinicians and patients come to understand 
uncertainty and equipoise. 
 
6.7  Patient autonomy, is it still far from Chinese patients? 
In developed countries, patients are being expected to take a more active role in the 
management of their health. In recent years the UK government has introduced a range 
of health reforms, including recommendation for greater patient choice in healthcare 
options95. The Wanless report96 called for a greater focus on effective health promotion 
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and active involvement of patients in their health care. In the Helsinki Declaration, the 
fundamental principle is respect for the individual, their right to self determination and 
the right to make informed decisions regarding participation in research, both initially 
and during the course of the research. However, patients’ autonomy was not considered 
an important issue in Chinese society97.  
 
Extreme trust in Chinese clinicians may lower patients’ incentives to participate in 
decision making. Although patients’ passivity in decision making is now discouraged98, 
patients who prefer passive roles generally have high, sometimes naïve, levels of trust99. 
Patients who totally depend on their clinicians to make medical decisions trust their 
clinicians significantly more than other patients do100. The belief ‘doctor knows best’ 
maybe due to the intense sense of vulnerability and anxiety that illness creates. 
Nevertheless, such unrealistic beliefs lower patients’ incentives to participate in shared 
decision making101. 
 
I questioned interviewees whether ‘for your treatment, would you like your clinician to 
make the decision for you, or for you two to discuss and make a decision together?’ 
100% of my interviewed patients answered ‘I prefer the clinician to make the decision 
for me’. In Western countries, patients’ autonomy is applauded by ethicists, which 
empowers patients to have more control over their medical treatment. The reality is that 
medical professionals would have some uncertainty about their clinical practice; patients 
should afford the final result then should be able to join clinicians to make decisions for 
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their own body. Sometimes patients may even have the opposite opinion to the clinician, 
and the clinician should follow the patient’s decision.  
 
Although patient’s medical freedom and autonomy is becoming increasingly popular in 
Western countries, in China patients are still cautious of clinicians’ opinion. It is likely 
that educated patients understand clinician’s uncertainty, but most of them prefer to 
ignore it; they are still willing to let clinicians resolve all the uncertainty for them. Patients 
believe that ‘clinicians are the professional persons in this area, but they are not. So 
their decision is certainly better than mine.’ This is a big difference between Chinese 
and Western patients, which may be the reason for high levels of compliance and low 
drop-out rates in Chinese RCTs.  Some research has found that increasing trust in a 
specific clinician is strongly associated with improved adherence to treatment 
regimens102;103. 
 
The limited number of Chinese medical doctors made patients is more willing to follow 
clinicians’ suggestions.  In China, the rate of medical doctor to total population is 
150/100,000, which is considered an ideal rate. However, those patients from rural 
areas, spend considerable time and money to arrive in urban hospitals. They care about 
their relationship with doctors. If the clinician has an opinion, they would find it difficult to 
refuse, because that means they damage the relationship and lose their clinician’s 
concern. And the result is may often be unaffordable’ to change clinician within hospital 
is quite hard and to change hospital is quite expensive. 
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6.8 What we learn from the comparison of RCT quality evaluation between 
different time periods 
 
I conducted updated Chinese RCT report quality evaluation of 2008-09, and made 
comparison with my previous study of 2004. I am glad to see the improvement on many 
clinical trial quality items, especially on those ethical issues; Chinese published RCTs 
had a rapid improvement. The improper procedure of having ethical approval and 
uninformed consent were always criticized by local and foreign media104;105. Therefore, 
the ethical regulation for medical research has been build as prior to other problems. It 
is certain that with the official regulation for medical research, more RCT papers 
declared they having ethical approval and participants’ informed consent in text. I 
consider this is a significant improvement both in RCT reporting and practical conduct.  
 
However, the quality of Chinese RCT report is a complex subject, which is relative to 
many items, such as medical authors’ (clinicians) understanding of the principle of RCT, 
medical journals’ publication requirement and the general accepted RCT standard in 
Chinese medical society, clinicians and participators’ attitude also affect the trial 
conduct and the trials’ result.  Therefore, in order to improve the quality of RCT 
reporting across the spectrum of quality items requires systematic work across all 
Chinese medical society. In my research, I just detect what the problems are, but to 
solve all of them, it need a series of substantial reforms. 
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In recent years, more and more Chinese and foreign medical researchers are caring 
about Chinese published RCTs, a series of publications of quality evaluation have been 
published106-109.  The common suggestion to Chinese publications is to accept 
CONSORT statement as the basic standard of RCT report. However, from my study, 
Chinese medical journals still haven’t taken this advice so far, and the RCT publications 
are still in low quality. Only one leading Chinese medical journal recommends 
CONSORT to their authors in journal’s ‘instruction and guide’. I found just through 
researchers’ publication to make a suggestion is not able to influence the whole medical 
society and make any reform. Further research need to be conduct to find what is the 
right way to make change. 
 
6.9 Suggestions from this thesis 
1. Chinese medical journal editors need to take training on the reporting of RCTs, 
and they need to set quality standards for their accepted Chinese RCT papers.  
2. All medical professionals and medical journal editors need to correct their attitude 
to positive result of RCT research, which is not the only standard of good RCT. 
3. Chinese general population needs to learn more about the RCT, public media 
should help lay public’s to understand RCT. Chinese public media or the 
hospitals would have more introduction on the basic knowledge of RCT, such as 
the basic principals and the meaning of informed consent, through public service 
announcement or publicity brochure. 
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4. Chinese medical society needs to take more concern about medical doctor’s 
research work; doctors need to have more opportunity to conduct medical 
research. 
5. The requirement of medical doctor’s research work should be various, publication 
as the only trace of doing research which need to be changed. For example, 
clinicians took time in patient recruitment of RCT, which could be record as their 
research work, and the amount of conducting research work could be 
accumulated as clinicians’ promotion requirement.   
Further research suggestions 
1. I could continue to assess the quality of Chinese published RCT, compared with 
Western leading medical journals, in order to detect whether Chinese RCTs are 
minimising the quality gap with Western research, and making Chinese RCTs 
acceptable to world medical society in the near future. 
2. The research on clinicians’ attitudes could to be extended national wide, in order 
to gain more generalisable information from clinicians. To understand clinicians’ 
attitude and barriers to the conduct of RCTs would be important to policy maker. 
 
6.10 Limitations 
I may have missed relevant studies not included in the database. The sample of Indian 
trials may not have been representative; my research would not have located all 
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published trials although my searches included Pubmed, ISI web of Science and the 
Journal Series of the Chinese Medical Association. 
 
Considering the large and disparate Chinese medical doctor population, the qualitative 
aspects of this study only involved a small number of doctors within one city. Therefore, 
further research should be conducted in this area in order to explore Chinese clinicians’ 
attitudes and in order to predict their behaviours in the future.   
 
All my interviewed clinicians and patients are nominated by the hospital, and all of these 
involved hospitals were nominated by the Guangzhou Public health bureau. The sample 
is not randomly selected; therefore, it could be that some selection bias exists affecting 
the result. I believe the results from my research is biased towards a positive outcome 
because those participators with good understanding and attitude would be nominated. 
 
Two hundred and fifty physicians were selected from 7378 doctors registered as fellows 
of the royal Australasian college of physicians (RACP) in May 2002. Fellows included 
clinicians, non-clinician, or retired doctors. They provide the data for the Western 
clinician’s data which was compared with my Chinese clinicians. All my Chinese 
clinicians are clinical doctors, and thus differ from Western participants.  
 
Western participants included retired doctors, but RCTs had been conducted since 
1940’s in Western countries, therefore, those retired clinicians are considered as 
experienced clinicians. Although the Chinese clinicians are younger than Australian 
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participants, but they are the first generation who had RCT experience; Chinese retired 
clinicians had no experiences of RCTs, because of the short history of Chinese RCT 
conduct. Non-clinicians are also including as Western participants , who had experience 
of management of support RCT conducts. However, in most Chinese hospitals, senior 
clinicians are taking management role in RCT conduct; there is limited staff taking 
support role in Chinese hospitals. 
 
All my Chinese participants are clinical doctors, but not all the Western participants, 
which would make affect to the comparison result. Chinese clinicians would report more 
about their practical conduct problems, but Western clinicians would have more 
management problems. Western clinicians might have more experiences but Chinese 
clinicians’’ expenses are limited. All Western clincians are random selected, but not my 
Chinese clinicans. Therefore, the attitude from Western clinicians may be more 
representative than the included  Chinese clinicians. 
 
China is a big country; the population of clinicians is also substantial. Although I 
conducted a survey in 3 large hospitals in Guangzhou, when compared to the clinician 
population of China, the findings are limited, which I have stated in the limitations 
section. However, my study was the original study in this area in China, and is the first 
to explore these issues among Chinese clinicians; having more accurate results of 
Chinese clinicians’ attitudes need more evidence from future research. 
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6.11 Conclusions 
 
The quality of Reporting of RCTs in China has improved between 2004 and 2008-09 
period, but which still requires substantial improvement to meet the targets of the 
CONSORT statement. In my work I identified strong evidence that Chinese RCTs are 
biased. The difference in positive results reported between Chinese trials and Western 
or Indian trials cannot plausibly be explained by the play of chance or the a priori 
identified confounding factors. Clinicians need more systematic training and incentives 
from the Chinese medical system. The RCT is not accepted properly by Chinese society, 
there are many cultural items which block RCT conduct in practice. Patients are 
influenced by traditional Chinese culture.  Patients’ rights of selection and determination 
need to be strengthened in Chinese society. 
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Appendixes 
 
Physicians Orientation Profile 
 
(Questions order is different from Chinese version) 
 
Primary allegiance 
 
Q1. Although many doctors are expected to perform both tasks, as a doctor my primary 
commitment is to: 
Future generations of patients (society) 
Present patients (individual) 
 
Q2. If I had to choose, I would say my primary task is: 
Caring for individual patients 
Contributing to scientific knowledge 
 
Q3. I would like to assess how successful I was as a physician by: 
My research contribution 
How I helped individual patients 
Both 
 
Q4. I would rather be somewhat: 
Too involved with my patients 
Too detached from my patients 
 
Q5. If a patient refuses to participate in a randomised clinical trial, I would: 
Treat the patient off the study 
Refer the patient to another doctor 
 
Q6. I would rather be known for: 
My interpersonal skills with patients 
My research accomplishments 
 
Q7. Overall I feel the quality of patient care: 
Increases when a patient is in a clinical trial 
Decreases when a patient is in a clinical trial 
                                                                                                                              181
Does not change when a patient is in a clinical trial 
 
Q8. Randomised clinical trials restrict my ability to individualise patient care:  
True  
Makes no difference  
 
Q9. I think the patient’s right to select treatment options is always more important than the 
advancement of scientific knowledge:  
True  
False 
 
Q10. Personal satisfaction is an important element of all professionals’ work. I get more 
satisfaction from: 
 
The work itself 
My patients/their family 
 
 
 
 
 
 
 
 
Decision –making under conditions of uncertainty 
 
 
Q11. When there is controversy in the literature as to which treatment is best: 
I enter the patient in a clinical trial if one exists 
I personally select the best treatment for the patient 
 
Q12. When making critical and controversial decisions, I usually: 
Seek major input from my patients 
Do not seek major input from my patients 
 
Q13. When published data and my clinical judgement conflict, I am more likely to rely on: 
My clinical experience 
Published data 
                                                                                                                              182
Q14. When a protocol includes a treatment that is more aggressive than I would usually give to 
similar non-trial patients:  
I am often reluctant to participate 
It makes no difference 
 
Q15. When a protocol includes a treatment that is less aggressive than I would usually give to 
similar non-trial patients:  
I am often reluctant to participate 
It makes no difference 
 
Q16. I am reluctant to participate in a trial that may randomise the patient to a “no treatment” 
group: 
Yes 
No 
 
Q17. When I am personally uncertain as to which treatment is best, I am likely to:  
Enter the patient in a randomised clinical trial if I am aware one exists 
Personally select a treatment 
 
Q18. When a potentially eligible patient chooses not to enroll on a trial that I have suggested: 
I often feel disappointed 
I seldom feel disappointed 
 
Q19.   As a physician, I am obliged to  
Follow medical tradition 
Question medical tradition 
 
 
 
Professional activities 
 
Q20. Ideally I would like to refer or enter the following proportion of my potentially eligible 
patients into randomised clinical trials: 
None 
Some 
Half 
Most 
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All 
Q21. The time I devote to publications, lectures and research commitments, compared to 
clinical work, is relatively: 
Totally clinical work 
Mainly clinical work 
Clinical and research equally 
Mainly research 
Totally research 
 
Q22. Frequent publications are important to my career advancement:  
Yes 
No 
 
Q23. I am more likely to attend a conference that focuses on:  
Clinical issues 
Research issues 
 
Perceived rewards 
 
Q24. In my hospital, doctors are given more reward for: 
Clinical skills with patients 
Contributing to scientific knowledge  
 
Q25. If written informed consent was not required, I would approach more patients to enter 
clinical trials 
True  
Makes no difference  
 
Q26. The need for detailed monitoring of my management of trial patients by trial staff deters 
me from participating in randomised clinical trials:  
Yes 
No 
 
Q27. The increased paperwork involved in treating patients on trials deters me from 
participating in randomised clinical trials: 
Yes 
No 
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Q28. The thought of having to spell out all the details of a trial to eligible patients discourages 
me from approaching them to participate: 
True  
False 
 
Q29. A major reason for my participation in randomised clinical trials is that it financially benefits 
my institution or department: 
Agree 
No 
 
Q30. Overall, involvement in randomised clinical trials:  
Enhances my reputation 
Does not enhance my reputation 
 
Q31. If research activities were to enhance my income, I would enter more patients in 
randomised clinical trials: 
Agree 
No 
 
Q32. When I participate in a randomised clinical trial, it is more likely that:  
I increase my patient population 
I lose patients I might otherwise keep 
It makes no difference to my patient population 
 
Q33. My income is dependent on my research activities: 
Yes 
No 
 
 
Peer-group influence 
Q.34. If you were to poll my staff, they would probably say I was particularly ‘good with patient’ 
Yes  
No  
 
 
Q35. In my hospital the pressure to participate in a randomised clinical trial is relatively:  
Low 
High 
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Q36. Of all eligible patients, I approach to participant in clinical trial, they agree: 
Less than 50% 
More than 50% 
 
 
